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Abstract 
Anabolic androgenic steroids (AAS) and associated drug use is now recognised as a 
significant concern and an emerging public health issue. Once restricted to the elite sporting 
arena, recent decades have seen AAS diffuse through bodybuilding and gym culture to an 
increasingly image conscious general population. This portfolio of research contributes to 
our understanding of this phenomenon in relation to our understanding of the extent and 
characteristics of AAS use, emerging harms and the policy response to the issue, as 
summarised below. 
 
While specific prevalence is unknown, data from needle and syringe programmes (NSPs) 
indicate growing numbers of people who inject AAS and associated drugs. Often portrayed 
in the media as a homogenous group of young male, working class men, a growing body of 
research indicates a much more diverse population in relation to demographic 
characteristics and motivations for use. Further research indicates that this is by no means 
confined to the United Kingdom (UK) but is a global public health issue although barely 
recognised in some countries such as the Republic of Ireland. 
 
Changes in the specific drugs of use and the regimes employed have been identified, with a 
growing pharmacopeia of easily accessible and affordable peptide hormones being used as 
a direct result of the rise of the Internet, coupled with developments in manufacturing and 
transportation. Opinion, anecdote and targeted marketing on the Internet fill the void of a 
lack of empirical evidence in the field of AAS, image and performance enhancing drugs 
(IPEDs) influencing a trend towards higher dosages, multiple drugs and prolonged use. Drug 
use is not confined to IPEDs, with psychoactive drug use identified in populations in UK and 
Internationally.  
 
Our understanding of the chronic health harms associated with AAS has increased over the 
last 25 years, in particular cardiovascular damage, psychological harms and the potential for 
dependence. However, this research has made a significant contribution to the recognition 
and understanding of the harms associated with the administration of these drugs through 
injection and the impact of adulterated products as a result of the illicit market. The extent 
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of localised infection and soft tissue injury is a cause for concern, an issue previously 
neglected. Of further concern is the prevalence of blood borne virus (BBV) infection within 
the population of AAS users. In the first studies of their kind, HIV amongst AAS injectors has 
been shown to be at a similar level as that in psychoactive drug injectors in the UK. Hepatitis 
B and hepatitis C levels were identified as being higher than in the general population, and 
of key concern is the low levels of awareness of hepatitis C positive status amongst AAS 
injectors. 
 
The UK has operated a comprehensive NSP system since the 1980s, which has seen 
increasing numbers of AAS injectors however, there remains barriers to engagement with 
this population of people who inject drugs. Data from interviews and surveys submitted 
here identify a level of mistrust and lack of confidence among AAS users when it comes to 
engaging with health professionals.  
 
The following thesis, submitted in partial fulfilment of the requirements of Liverpool John 
Moores University for the degree of Doctor of Philosophy spans over twenty years of 
academic work within the specific field of AAS use. The research provides the groundwork 
for the development of meaningful and successful policies and interventions to reduce harm 
and promote health based on the need of this population. The submission includes a brief 
critical reflection on the undertaken research and the engagement with the research 
population, drawing on my experiences, positionality and evolution of knowledge and 
understanding. This further informs the concluding remarks and suggestions for future 
research. 
 
The key contribution of the following portfolio of work can be summarised as follows: 
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Summary of contribution to evidence and understanding of AAS use 
 
Changes in extent, characteristics and practices of AAS users  
 Significant increases in the number of AAS injectors engaging with NSP across UK. 
 Health service gap for AAS users who do not inject  
 Diffusion of use from central urban post-industrial cities to suburban and rural areas. 
 Increased numbers of older AAS users due to cohort effect and later onset of use. 
 More diverse motivations for use, typology of user and risk profile. 
 High levels of psychoactive drug use amongst AAS users. 
 Population of AAS users who have previously injected psychoactive drugs. 
 Increasing prevalence of human growth hormone. 
 Increased use of new peptide hormones including melanotan, MGF and GHRP-6. 
 Re-emergence of DNP amongst AAS users and its diffusion to the wider population. 
 Increased dosages, longer cycles and the introduction of “blast & cruise” regimens.    
 
Evidence of harm related to the use of AAS and associated drugs 
 Confirmation of established harms through systematic review 
 Significant number of HIV positive users of AAS in the United Kingdom.  
 Hepatitis B and hepatitis C infection amongst AAS users. 
 Low levels of hepatitis c testing and diagnosis amongst AAS using population.  
 Psychoactive drug use, sex between men and imprisonment predictive of infection. 
 Sharing of injecting equipment amongst sub-populations of AAS users. 
 High levels of unprotected sex amongst AAS users. 
 Common localised infection such as abscess formation and soft tissue injury. 
 Adulteration and substitution of active ingredients resulting in harm. 
 Wide variation in strength of illicitly manufactured AAS and associated drugs. 
 Adulteration of supplements with AAS and associated drugs. 
 The ease of availability and low understanding of risks associated with DNP. 
 
The health and drug policy response to the emerging public health issue 
 NSPs in UK engaged with large numbers of AAS injectors. 
 Wide variation in NSP service uptake and engagement across the UK.   
 Little evidence of effectiveness of engagement strategies with AAS users. 
 Mistrust of academics and health service amongst many AAS users. 
 Reluctance of AAS users to declare use or seek treatment for harms. 
 Blood borne virus testing and vaccination remains low amongst AAS users. 
 Inadequate response to AAS use in Ireland. 
 Potential for greater engagement of AAS users via sexual health services. 
 Recognition of AAS use within UK clinical guidelines and drugs policy. 
 Legislation changes have not impacted on prevalence of AAS use. 
 Negative unintended health consequences of legislation. 
5 
 
 
Public health impact and implications of the use of anabolic androgenic 
steroids (AAS) and associated drugs amongst the male general population. 
Contents 
Section 1: Portfolio of work ....................................................................................................... 7 
1.1 Peer-reviewed articles submitted for PhD with contribution to submitted work .......... 7 
Section 2: Introduction ............................................................................................................ 10 
2.1 Introduction to thesis ................................................................................................ 10 
2.2 Introduction to AAS and associated drug use amongst the general population ...... 12 
Section 3: Methodology and theoretical framework .............................................................. 24 
3.1 Methodology and limitations ........................................................................................ 24 
3.2 Theoretical approach ..................................................................................................... 25 
Section 4: Changes in extent, characteristics and practices of AAS users ............................... 28 
4.1 The extent of anabolic androgenic steroid use ............................................................. 30 
4.2 Characteristics of users .................................................................................................. 31 
4.3 Changes in practice and usage ....................................................................................... 34 
4.4 Conclusion ...................................................................................................................... 37 
Section 5: Evidence of harm related to the use of AAS and associated drugs ................... 39 
5.1 Established adverse effects of AAS. ............................................................................... 41 
5.2  Adverse effects associated with injecting behaviours .............................................. 41 
5.2.1 HIV, hepatitis B and hepatitis C ......................................................................... 42 
5.2.2 Injection site injuries and infections ....................................................................... 43 
5.3  Harms associated with adulterated and contaminated AAS and associated drugs . 44 
5.4 Conclusion ...................................................................................................................... 46 
Section six:  The health and drug policy response to the emerging public health issue ...... 48 
6.1 Health policy response to AAS use ................................................................................ 49 
6.1.2 Response to BBV transmission in the UK and internationally ................................ 50 
6.1.3 Engagement and barriers ........................................................................................ 51 
6.1.4 The impact of changes in UK drugs legislation on the use of anabolic androgenic 
steroids............................................................................................................................. 52 
6.2 Conclusions .................................................................................................................... 53 
Section 7: Conclusion and future direction ............................................................................. 54 
Section 8: References............................................................................................................... 60 
 
 
6 
 
 
 
Appendix I: Submitted Papers 
  
1) Zahnow, R., McVeigh, J., Bates, G., Hope, V., Kean, J., Campbell, J., & Smith, J. (2018) 
Identifying a typology of men who use Anabolic Androgenic Steroids (AAS). International 
Journal of Drug Policy. 55, 105-112 
 
2) McVeigh, J., & Begley, E. (2017). Anabolic steroids in the UK: an increasing issue for public 
health. Drugs: Education, Prevention and Policy, 24:3, 278-285  
 
3) Zahnow, R., McVeigh, J., Ferris, J., & Winstock, A. (2017). Adverse effects, health service 
engagement, and service satisfaction among anabolic androgenic steroid users. 
Contemporary Drug Problems 44(1):69-83 01  
 
4) McVeigh, J., Germain, J., & Van Hout, M. C. (2016). 2,4-Dinitrophenol, the inferno drug: a 
netnographic study of user experiences in the quest for leanness. Journal of Substance Use, 
22(2), 131-138.  
 
5) McVeigh, J., Hearne, E., Bates, G., & Van Hout, M. C. (2016). Community pharmacist 
experiences of providing needle and syringe programmes in Ireland. Research in Social and 
Administrative Pharmacy. S1551-7411(16)30310-2  
 
6) Kimergard, A., & McVeigh, J. (2014). Environments, risk and health harms: a qualitative 
investigation into the illicit use of anabolic steroids among people using harm reduction 
services in the UK. BMJ Open, 4(6), 7 pages. doi:10.1136/bmjopen-2014-005275 
 
7) Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., 
Croxford S., Beynon C. M., Parry J. V., Bellis, M. A. & Ncube F. (2013).  Prevalence of, and risk 
factors for, HIV, hepatitis B and C infections among men who inject image and performance 
enhancing drugs: a cross-sectional study. BMJ OPEN, 3(9),  
 
8) McVeigh, J., Beynon, C., & Bellis, M. A. (2003). New challenges for agency based syringe 
exchange schemes: Analysis of 11 years of data (1991-2001) in Merseyside and Cheshire, 
United Kingdom. International Journal of Drug Policy, 14(5-6), 399-405.  
 
Appendix II: Supplemental material 
Appendix II.1 Supplemental peer-reviewed journal papers 
Appendix II.2 Additional peer-reviewed journal papers, editorials, systematic reviews 
Appendix II.3 Selected minor peer reviewed papers, reports and book chapters 
Appendix II.4 Examples of plenary and keynote conference presentations (Last 12 months) 
 
  
7 
 
Section 1: Portfolio of work 
 
1.1 Peer-reviewed articles submitted for PhD with contribution to submitted work 
 
1) Zahnow, R., McVeigh, J., Bates, G., Hope, V., Kean, J., Campbell, J., & Smith, J. (2018) 
Identifying a typology of men who use Anabolic Androgenic Steroids (AAS). International 
Journal of Drug Policy. 55, 105-112 
Journal Impact Factor 3.48 Citations – 4 Altmetric 9  
Contribution: Second author responsible for conception of study, co- development of 
methodology and 40% writing of paper. 
 
2) McVeigh, J., & Begley, E. (2017). Anabolic steroids in the UK: an increasing issue for public 
health. Drugs: Education, Prevention and Policy, 24:3, 278-285 
doi:10.1080/09687637.2016.1245713. 
Journal Impact Factor 0.94* Citations – 13 Altmetric 104  
* selected as a top published paper over the last 25 years 
Contribution: Principle author responsible for conception of study, development of 
methodology analysis and writing of paper. 
 
3) Zahnow, R., McVeigh, J., Ferris, J., & Winstock, A. (2017). Adverse effects, health service 
engagement, and service satisfaction among anabolic androgenic steroid users. 
Contemporary Drug Problems 44(1):69-83 01 doi:10.1002/dta.1728 
Journal Impact Factor 0.59 Citations – 5 Altmetric - 1 
Contribution: Second author responsible for conception of study, co- development of 
methodology, co-analysis and 40% writing of paper. 
8 
 
 
4) McVeigh, J., Germain, J., & Van Hout, M. C. (2016). 2,4-Dinitrophenol, the inferno drug: a 
netnographic study of user experiences in the quest for leanness. Journal of Substance Use, 
22(2), 131-138. doi:10.3109/14659891.2016.1149238 
Journal Impact Factor 0.77 Citations - 3 Altmetric 5 
Contribution: Principle author responsible for conception of study, development of 
methodology analysis and analysis and writing of paper. 
 
5) McVeigh, J., Hearne, E., Bates, G., & Van Hout, M. C. (2016). Community pharmacist 
experiences of providing needle and syringe programmes in Ireland. Research in Social and 
Administrative Pharmacy. S1551-7411(16)30310-2 doi:10.1016/j.sapharm.2016.07.006 
Journal Impact Factor 2.20 Citations - Altmetric 8 
Contribution: Principle author responsible for conception of study, development of 
methodology analysis and analysis and writing of paper. 
 
6) Kimergard, A., & McVeigh, J. (2014). Environments, risk and health harms: a qualitative 
investigation into the illicit use of anabolic steroids among people using harm reduction 
services in the UK. BMJ Open, 4(6), 7 pages. doi:10.1136/bmjopen-2014-005275 
Journal Impact Factor 2.37 Citations 13 Altmetric - 15 
Contribution: Second author responsible for conception of study, co-development of 
methodology, co-analysis and 45% writing of paper. 
 
7) Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., 
Croxford S., Beynon C. M., Parry J. V., Bellis, M. A. & Ncube F. (2013).  Prevalence of, and risk 
9 
 
factors for, HIV, hepatitis B and C infections among men who inject image and performance 
enhancing drugs: a cross-sectional study. BMJ OPEN, 3(9), 11 pages. doi:10.1136/bmjopen-
2013-003207 
Journal Impact Factor 2.37 Citations – 43 Altmetric - 49 
Contribution: Second author responsible for co-conception of study, co-development of 
methodology and 35% writing of paper. 
 
8) McVeigh, J., Beynon, C., & Bellis, M. A. (2003). New challenges for agency based syringe 
exchange schemes: Analysis of 11 years of data (1991-2001) in Merseyside and Cheshire, 
United Kingdom. International Journal of Drug Policy, 14(5-6), 399-405. doi:10.1016/S0955-
3959(03)00141-5 
Journal Impact Factor 3.47 Citations – 29 Altmetric - 
Contribution: Principle author responsible for conception of study, development of 
methodology, co-analysis and writing of paper. 
 
 
 
Total citations of the 8 submitted publications : 110  
 
All Journal Impact Factors, Citations and Altmetrics scores are accurate as of 14th February 
2018 (Symplectic, 2018). 
 
 
  
 
  
10 
 
Section 2: Introduction 
 
2.1 Introduction to thesis 
 
The following introduction (2.2) provides context to the thesis ‘Public health impact and 
implications of the use of anabolic androgenic steroids (AAS) and associated drugs 
amongst the male general population’. It provides a brief historical perspective, leading to 
the point of commencement of the research submitted for this thesis. It is required in order 
to evidence the significant contribution of the submitted research and how the portfolio of 
work has changed our understanding of the phenomenon. The review draws on both 
scientific literature in the form of peer-reviewed journal papers and academic books and 
importantly, includes literature produced by those who are part of the AAS using 
community. The ‘underground literature’ has had a significant impact on drug use practices 
and risk behaviour often filling the void of inadequate academic evidence. Therefore, to gain 
a thorough understanding of the issues associated with the use of AAS,  it is essential that 
the work of cultural innovators such as Dan Duchaine, William Phillips and William Llewellyn 
(Phillips, 1991, Llewellyn and Tober, 2010, Duchaine, 1989, Llewellyn, 2017) 1 are viewed 
alongside the academic outputs of the leading academics such as Pope and Yesalis  (Pope 
and Kanayama, 2012, Pope and Katz, 1992, Pope et al., 2016, Pope et al., 2000, Yesalis, 
1992, Yesalis and Bahrke, 2002, Yesalis et al., 1989).  
 
                                                     
1 Bill Phillips and to an even greater extent Dan Duchaine were the most influential icons of the anabolic 
steroid using communities in the United States and United Kingdom during the 1980s and 1990s. While largely 
based on experience and local observation, their publications were used as manuals of use and their views 
rarely questioned. Bill Llewellyn has been highly influential over the last 20 years, with a web presence, media 
exposure and popular publications, his outputs are extensively researched, referenced and accessible to the 
AAS user community. 
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The focus of the research and following thesis is the use of AAS and associated drugs by 
men. The use of these drugs is by no means restricted to men, literature over time and 
across geographical areas have all indicated that use does occur amongst women, albeit at 
significantly lower levels (Sagoe et al., 2014c, Bahrke et al., 1998, Buckley, 1988, Hakansson 
et al., 2012, Broadfield, 2017). While there is limited research on the use of these drugs by 
women, the literature indicates significant differences to their male counterparts in relation, 
to motivations and drivers, practices and effects (Ip et al., 2010, Gruber and Pope, 1999, 
Strauss et al., 1985, Malarkey et al., 1991, Gerritsma et al., 1994).  Early research conducted 
with colleagues (Korkia et al., 1996) provided clear evidence that while there exists 
commonality amongst both male and female AAS users, the female specific  issues are such 
that they warrant a separate approach, analysis and commentary, beyond the scope of this 
thesis. 
 
The introduction also aims to provide the rationale for the content of the submitted 
research. Namely, to inform our understanding of three major issues in relation to the 
public health impact and implications of AAS and associated drug use amongst the general 
population; i) the extent, characteristics and practices of users; ii) harm related to use; iii) 
the policy response to this emerging public health issue. These three issues correspond to 
sections four to six of the thesis, where the results of the submitted research papers are 
discussed. Prior to the three results sections, section three examines the methodology, 
limitations and theoretical approach to the research portfolio.  
 
Sections four to six continue from the point of completion of the following introduction and 
have a strong focus on the UK. The exception to this is section six, examining the policy 
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response to anabolic androgenic steroid use, in particular, that by health services. In doing 
so, it includes findings from two studies submitted as part of this thesis. One drawing on 
analysis from the Global Drug Survey (Paper 3), the other exploring needle and syringe 
provision in Ireland (Paper 5), a country at the early stages of AAS service development. 
 
Section seven: provides a brief summary to the thesis together with implications for future 
policy and research.  
 
2.2 Introduction to AAS and associated drug use amongst the general population 
 
Pharmacologically active agents, usually referred to as drugs, are administered or self-
administered for a number of different purposes and with various motivations. While the 
self-administration of illicitly obtained drugs is often portrayed and perceived as a 
hedonistic pursuit of pleasure, this is not always the case. Rather than the instant 
gratification, euphoria or stimulation produced by a drug, the purpose may be 
predominantly functional, taken in an attempt to improve or enhance an individual’s 
abilities or appearance (Juengst, 2000, McVeigh et al., 2012a, Savulescu et al., 2011). This is 
the focus of my portfolio of work, which examines the use of functional enhancement drugs 
over the last 20 years, in particular AAS use in the UK and within a global context. 
 
Human enhancement drugs and their usage is by no means a new phenomenon, with 
records of its use in social, ritual and sporting contexts throughout recorded history. Over 
the past thirty years there has been growing evidence related to human enhancement 
drugs, the associated epidemiology and the potential harms. However, it is only in the last 
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decade that human enhancement drugs have been formally categorised into distinct 
groups, based on their function rather than pharmacological properties. These comprise six 
general classes; structure and function of muscle; weight loss; cosmetic; appearance of the 
skin and hair; sexual behaviour and function; cognitive function; mood and social 
behaviours (Evans-Brown et al., 2012, McVeigh et al., 2012a). This work has led to 
subsequent research and academic investigation into these diverse types of drug use under 
a broad term of Human Enhancement (Brennan et al., 2016, van de Ven and Koenraadt, 
2017) 
 
It is the category of drugs consumed with the intent of enhancing structure and function of 
muscle that is the primary focus of my research portfolio. Diverse substances consumed for 
the purpose of sporting performance and muscular enhancement can be found in literature 
dating back to ancient civilisations such as Greece and Rome. While the veracity of accounts 
from the earliest recorded civilisations may be questionable they reflect a common drive for 
muscular enhancement (both size and function)  in many global and historical cultures 
(Taylor, 1991, Csaky, 1972). 
 
The most prevalent, well-established and infamous group of drugs within the spectrum of 
human enhancement drugs are the AAS (Evans, 2004, Evans-Brown and McVeigh, 2009a, 
Pope et al., 1988, Pope and Katz, 1992, Kanayama et al., 2010b, Yesalis, 1992, Korkia and 
Stimson, 1993, Bahrke and Yesalis, 2004, Yesalis and Bahrke, 1995, Buckley, 1988). 
Testosterone, required for normal functioning and health (Nieschlag and Behre, 2004, 
Nieschlag et al., 2004) was first isolated and synthesised 1935 (Yesalis and Bahrke, 1995, de 
Kruif, 1945).  This resulted in the development of the related chemicals, namely anabolic 
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androgenic steroids (AAS) (ACMD, 2010b, Hoberman and Yesalis, 1995, de Kruif, 1945). The 
androgenic effects of these drugs are associated with masculinisation, essential 
reproductive function and the development of secondary male characteristics while the 
anabolic component is related to protein building in skeletal muscle and bone. (Kochakian, 
1975, ACMD, 2010b, ACMD, 2010a, Kicman, 2008b). The anabolic components cannot be 
entirely separated, something which has been attempted since the first anabolic androgenic 
steroid, Dianabol, went into production in the 1950s (Fair, 1993, Taylor, 1991). While it is 
useful to view the effects of testosterone and therefore AAS within the simple categories of 
anabolic and androgenic, testosterone acts on many systems throughout the body resulting 
in changes in cardiovascular function, the immune system, mood and behaviour (Nieschlag 
et al., 2004, Kicman, 2010, Kicman et al., 2010).  
From the 1950s, the use of AAS quickly spread through competitive sport, in particular 
those sports relying on power and strength (Kruskemper, 1968, Voy, 1991, Todd, 1987, 
Dubin, 1990, Wright, 1978, Dimeo, 2007) and into the aesthetic and recreational sporting 
domains. Whilst the media and much of society have focused predominately on the use of 
AAS within elite sport, the use of testosterone and AAS for wellbeing and general human 
enhancement has also grown in popularity.  
 
Rooted in the practice of ‘organotherapies’, ‘patent medicines’ and ‘secret remedies’ of the 
early twentieth century   (Evans-Brown et al., 2012, Hoberman, 2001, BMA, 1909), the 
prescription of testosterone became fashionable for a period from the 1940s in the United 
States (Hoberman and Yesalis, 1995). As recently as 1953, physicians in publications such as 
the Journal of the American Medical Association were discussing the values and relative 
safety of prescribing testosterone to enhance vitality and feelings of wellbeing (Hoberman, 
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2001). However, the advent and marketing of the new AAS from the mid 1950s resulted in 
increasing interest in these substances to both aid sporting performance and to enhance 
musculature for physique. 
 
The use of AAS within the gym culture was well established in parts of the United States by 
the 1970s, having first been introduced by elite and ‘avant garde’ bodybuilders from the late 
1950s and 1960s (Hoberman and Yesalis, 1995, Yesalis et al., 1989, Evans-Brown et al., 
2012). Bodybuilding had gained significantly in popularity in the United States (Parish et al., 
2010), as society, driven by mass media (Longobardi et al., 2017, Leit et al., 2002), began to 
equate masculinity with high levels of muscularity (Cafri et al., 2005, Cafri et al., 2006). The 
use of AAS within the general population in the UK appears to have arrived later that the 
United States and may be classed as relative ‘late adopters’ in comparison to the 
‘innovators’ and ‘early adopters’ of the United States (Rogers, 1983, Rogers, 1995, De Tarde, 
1903, Zinberg, 1984). Although the use of AAS within bodybuilding in the UK was reported in 
the medical literature of the 1960s (Pearson, 1967, MacQueen, 1967) it wasn’t until the 
1980s that widespread use within the gym culture was identified (Lenehan et al., 1996). 
 
The 1980s saw the first prevalence studies of AAS use in the United States. Whilst individual 
and team case studies reported specific instances of use amongst young males as early as 
1959 (Yesalis et al., 2000b), it was a landmark prevalence survey  (Buckley, 1988) that set 
the methodology for much of the subsequent prevalence research. This study identified an 
AAS prevalence of 6.6% amongst 12th grade male United States students. Based on this 
methodology, subsequent surveys supported these finding (Komoroski, 1992, Tuttle et al., 
1994, Johnson et al., 1989, DuRant et al., 1993, DuRant et al., 1995, Whitehead et al., 1992, 
16 
 
Luetkemeier et al., 1995, Middleman et al., 1995, Bahrke et al., 1998, Stilger and Yesalis, 
1999) with prevalence estimates ranging between 3% and 12% in the United States (Yesalis 
et al., 2000a). By the mid-1990s, with research stimulated following the Ben Johnson 
scandal of 1988 (Dubin, 1990, Francis, 1990), similar adolescent prevalence studies were 
conducted in Canada (Melia et al., 1996), Sweden (Nilsson, 1995), with both indicating high 
levels of usage. Prior to 2000, few other surveys were conducted outside United States.  
 
In the UK, to date, no such adolescent prevalence studies have been conducted, however 
there were a number of case reports and small-scale studies within private gymnasia 
(McKillop, 1987, Garner and Miles, 1985). These reports were supplemented by a number of 
press reports, and in particular the UK newspaper The Times (Evans-Brown and McVeigh, 
2009a, Evans-Brown et al., 2012). By the mid-1990s, a number of studies had been 
published highlighting the extent of AAS use in the UK. Although mostly descriptive and 
based on small samples in discrete geographical locations (Williamson, 1993, Perry et al., 
1992, Perry and Littlepage, 1992), two influential studies were conducted during this period, 
a prevalence study of those attending gymnasia across the Great Britain (Korkia, 2000, 
Korkia and Stimson, 1997, Korkia and Stimson, 1993) and a large scale study in the North 
West of England (Lenehan et al., 1996).  
 
The work of Korkia et al. (1993) found that 6% of men and 1.4% of women were current 
users of AAS while the work of Lenehan et al (1996), based on 1954 gym attenders, found 
that 26.7% were current users of AAS. The surveys also illustrated a wide variation of 
prevalence dependent on the characteristics of the gym. The surveys both had additional 
interviews with AAS users, 110 in the national study (Korkia, 2000, Korkia and Stimson, 
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1997, Korkia and Stimson, 1993) and an additional 386 in the North West of England 
(Lenehan et al., 1996). The results gave the first robust evidence of a large population of 
AAS users in the UK, whose motivation for use was primarily for aesthetic purposes. Users of 
AAS could be placed in three broad categories, the majority of whom are male (AAS use in 
females appears to be predominantly limited to bodybuilders and sportswomen (Korkia et 
al., 1996, Lenehan et al., 1996, Korkia, 2000, Korkia and Stimson, 1997, Korkia and Stimson, 
1993, Evans-Brown and McVeigh, 2009a). While users may fall within more than one group 
and change over time they were thought of as: 1) competitive athletes; 2) occupational 
users (including security, manual workers and entertainers ; and, 3) recreational users (using 
for aesthetic purposes)  (Lenehan, 2003, Lenehan and McVeigh, 1998) with by far the largest 
group being the recreational users (Evans-Brown and McVeigh, 2009a). 
 
In 1996, AAS and a range of associated drugs were controlled under the Misuse of Drugs Act 
(1971) as Class C (Lenehan, 2003, Lenehan and McVeigh, 1998, Evans-Brown and McVeigh, 
2009a, Evans-Brown et al., 2012, ACMD, 2010b). This made them prescription only 
medicines therefore only lawfully sold or supplied in accordance with a prescription from an 
appropriate practitioner. However, it remained legal to possess or import/export AAS as 
long as they were intended for personal use and in the form of a medicinal product. This 
change in the legislation was largely based on the perceived potential for harm associated 
with their use (ACMD, 2010b), although this premise was disputed on the grounds of 
insufficient evidence, both within the academic community (Korkia, 1998a) and the lay AAS-
using community (Hart, 1993)2 of the UK. 
                                                     
2 Mick Hart was a former United Kingdom bodybuilder, gym owner, AAS user and self-styled media expert on 
AAS during the 1990s and 2000s. 
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The 1990s through to the early 2000s witnessed a growing understanding of AAS actions 
and effects (ACMD, 2010a, Kicman, 2008a, Kicman and Gower, 2003, Kicman et al., 2010). 
This included conclusive evidence for the potential enhancement and growth of skeletal 
muscle (Bhasin et al., 1996, Bhasin et al., 2001), until this point a disputed theory. Despite 
clear indications to the contrary both the British Association of Sports Medicine (BASM) and 
the American College of Sports Medicine (ACSM) position statements of the 1970s had 
denied the potential benefits of AAS (Taylor, 2001), with the former President of the ACSM, 
Dr A.J. Ryan was reported to have referred to them as a “fool’s gold”(Pampel, 2007). The 
position statement of the of ACSM included the following line, as recounted by Bob 
Goldman, “There is no conclusive evidence that extremely high dosages of AAS either aid or 
hinder athletic performance” (Goldman, 1984). These statements had remained in 
circulation for many years, despite cultural and ethno pharmacological knowledge to the 
contrary (Duchaine, 1989, Phillips, 1991, Chinery, 1993, Gallaway, 1997).   
 
Whilst there were significant gaps in the scientific literature in relation to the epidemiology 
of AAS use, there was increasing knowledge and understanding of the methods and 
practices of use. Key sources of information were the “underground literature”, providing 
guides to drug regimes, including dosages, specific AAS and ancillary drugs. The influence of 
underground literature (predominantly from the United States) on the AAS using 
community could be seen in research conducted in the UK. A high level of consensus 
emerged amongst the UK research (Korkia and Stimson, 1993, Lenehan et al., 1996, Pates 
and Barry, 1996, Burton, 1996) indicating that the majority of users were taking several 
different AAS simultaneously, relatively low levels of other anabolic hormones (such as 
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human growth hormone), but a range of other drugs such as thyroxine (Dawson and 
Harrison, 1996) nalbuphine (McBride et al., 1996) and gammahydroxy butyrate (GHB) 
(Lenehan and McVeigh, 1998). Drugs such as nalbuphine and GHB could be traced back to 
literature by Dan Duchaine (Duchaine, 1989). Drugs used to counter the adverse effects of 
AAS such as tamoxifen and human chorionic gonadotrophin were also advocated by the  
‘steroid gurus’ Duchaine (1989) and Phillips (1991) and adopted by users in the UK (Aguilera, 
1999, Lenehan et al., 1996, Korkia and Stimson, 1993). 
 
Until relatively recently, there remained significant gaps in our understanding of the harms 
caused by the use of AAS and associated drugs. Many of the cosmetic effects caused by 
hormonal imbalance (e.g. virilisation and aromatization) had been well understood and 
documented for some time (Wright, 1982, Kochakian, 1976). Case reports of mortality and 
serious morbidity were compiled by Friedle in the 1990s, including serious conditions 
associated with the renal system (Prat et al., 1977, Bryden et al., 1995), hepatic system 
(Overly et al., 1984, Creagh et al., 1988, Cabasso, 1994, Yoshida et al., 1994) and cerebro-
cardiovascular system (Dickerman et al., 1995, Huie, 1994, Kennedy, 1992, Kennedy and 
Lawrence, 1993, Ferenchick and Adelman, 1992, Lyngberg, 1991, Luke et al., 1990, Frankle 
et al., 1988, Mochizuki and Richter, 1988). However, even with the ever growing list of these 
reports Friedle concluded that: ‘Many “well established” risks are based on anecdotal 
experiences and misinterpreted science’ (Friedle, 1993). This supported the earlier 
conclusions of  Wright, a leading authority on AAS, who quoted the work of socio-biologist 
Garrett Hardin, stating that a side effect is simply: “any effect we don’t want, the existence 
of which we will deny for as long as we can” (Wright, 1978). In 1982 Wright went on to say 
that while there is a strong case to support the view that AAS can cause significant harm, 
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physicians were only just recognizing the flaws in generalizing adverse effects within a 
clinical population to that of fit and healthy sports participants (Wright, 1982). This 
contributed to the tension between the medical/scientific community and the subculture of 
the anabolic androgenic steroid users themselves, who to a large degree were not 
experiencing significant morbidity or mortality associated with their AAS use (Phillips, 1991, 
Duchaine, 1989). 
 
Prior to 2013, there was little evidence regarding the extent of Human Immunodeficiency 
Virus (HIV) infection amongst users of AAS and associated drugs. While the potential for 
transmission was clear (Lenehan and McVeigh, 1994), there were few specific cases 
identified and published (Scott and Scott, 1989, Sklarek et al., 1984, Henrion et al., 1992) 
and the issue gained little attention. In the UK data from surveillance of injecting drug users 
attending needle and syringe programmes in the 1990s identified only three cases of 
hepatitis B and no cases of HIV amongst a sample of 149 AAS users. This led the authors to 
conclude that the risk of blood borne virus transmission amongst AAS injectors was low 
(Crampin et al., 1998). Other research in the UK countered this with specific cases of 
hepatitis C infection amongst AAS injectors (Cook et al., 2000) and evidence of potential 
transmission amongst the community from sexual contact as well as through the specific 
sharing of injecting equipment (Best and Midgley, 1998, Midgley et al., 2000). 
 
Increasing numbers of academic papers citing the psychological effects of AAS, in particular 
those associated with aggression were published. This association was based on theoretical 
and observational animal work (Bahrke et al., 1996, Bahrke et al., 1990b), together with a 
number of studies by Pope (Pope and Katz, 1992, Pope and Katz, 1990, Pope and Katz, 1994, 
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Choi and Pope, 1994). However, a range of psychological changes were compiled as early as 
1984, including both positive effects such as increased alertness and focus and desire to win 
together with increased aggression, violence and psychosis (Taylor, 1991). During the 1990s 
these were confirmed by other researchers (Korkia, 1998b, Bahrke et al., 1990b, Parrott et 
al., 1994) and additional symptoms identified such as affective disorders (Perry and Hughes, 
1992) and mania (Su et al., 1993) together with earlier cases identified and referenced, such 
as that of schizophrenia (Annitto and Layman, 1980). Issues related to aggression were a 
growing concern, particularly in the United States (Bahrke et al., 1992, Bahrke et al., 1990a, 
Pope and Katz, 1990, Pope and Katz, 1994). Research at this time in the UK revealed self-
reports of aggression being commonplace amongst AAS users, with police officers also citing 
a link between AAS and serious violent crimes (Bristow, 1988). However, accounts of 
aggression being used instrumentally to facilitate training were also published at this time 
(Lenehan et al., 1996, Korkia and Stimson, 1993, Evans-Brown and McVeigh, 2009a). 
 
 In the development of evidence relating to dependence on AAS, a similar situation could be 
observed, with increasing literature from the United States (Brower et al., 1989, Brower et 
al., 1990, Brower et al., 1991a, Brower et al., 1991b, Bahrke et al., 1990b, Pope and Katz, 
1992, Bahrke and Yesalis, 1994). In the UK, a range of adverse effects were described on 
cessation of AAS including depression (13.2%), dissatisfaction with body image (10.8%), and 
feelings of wanting to take more steroids (16.9%). Additionally, 3.2% of those interviewed 
reported suicidal thoughts on discontinuation of use (Lenehan et al., 1996, ACMD, 2010b), 
supporting earlier work in the United States published in 1985 (Taylor, 2001). 
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While an increasing number of studies into the effects (both positive and negative) of AAS 
and associated drugs were conducted and findings published during the 1980s and 1990s 
there remained many contradictions. This lack of consistency in the evidence base has been 
attributed to a number of factors including variations in study design and methods, use of 
non-validated scales, inconsistent recording of variables such as dosage, the self-reported 
nature of many studies and the placebo/nocebo effect of AAS (Bahrke and Yesalis, 2002). A 
significant additional confounding factor in relation to the illicit market has also been 
identified. With many available AAS being manufactured illicitly without adequate quality 
assurance it may be concluded that if “…the composition of the drug products cannot be 
assured and we do not quantify and assess the impact of this, then how can we know if we 
are examining the effects of a specific drug product?” (Evans-Brown et al., 2009b). Despite 
the caveats to the evidence base, the conclusions regarding adverse effects were (to varying 
degrees) supported amongst the AAS using community (Phillips, 1991, Duchaine, 1989).  
 
The policy response to the issues related to AAS were highly variable between countries, 
with the major influences being sporting authorities, criminal justice agenda (including illicit 
drug controls) and the health agenda (including harm reduction). With regards to the policy 
response in the United States and the UK, they could be described as polar opposites. The 
UK controlled AAS under the Misuse of Drugs Act (1971) in 1996, this did not criminalize 
personal possession (ACMD, 2010b). The United States passed legislation in 1988, classing 
unlawful supply as a felony, however, prior to this, personal possession of AAS without a 
prescription was already classed as unlawful in all 50 states (Kleinman and Petit, 1993, 
Yesalis et al., 1997). So, while the United States focus was criminalisation, this was not the 
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case in the UK, who instead of driving AAS use further underground took a pragmatic stance 
to promote health and reduce harm. 
 
Unlike the United States, the UK had adopted a harm reduction strategy in the mid-1980s, 
as a result of increased concerns relating to the transmission of HIV (Stimson, 1995). The 
policy did not only focus on the prevention of blood borne viruses but on wider 
interventions to reduce the health, social, and economic harms to individuals, communities, 
and society associated with the use of drugs. This policy saw AAS users utilizing needle and 
syringe programmes from the early 1990s (and earlier in some parts of the UK) (Birtles, 
1998). It also aimed to facilitate the engagement of AAS users with generic health services, 
with some success (Dawson, 2001) (Perry et al., 1994). While the UK embraced the ethos of 
harm reduction, at least one physician in Australia took the step of prescribing AAS to 
patients for the purpose of muscular enhancement (Millar, 1996, Millar, 1998, Millar, 1994, 
Lenehan, 2003). While adverse effects in this instance were minimal and most patients 
achieved their goals without prolonged use, the experimental intervention was not widely 
replicated (Millar, 1996). 
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Section 3: Methodology and theoretical framework 
 
3.1 Methodology and limitations  
A mixed methods approach has been used in this portfolio of research. The primary purpose 
of this work is to assess the public health impact and implications of the relatively new 
phenomenon of AAS and associated drug use in the general population. Therefore, a variety 
of methodologies have been employed: 
Paper 1 Indigenous fieldworker interviews, cluster analysis and logistic regression to identify 
characteristics and motivations for use (Zahnow et al., 2018). 
Paper 2 Surveillance data, historical/policy analysis to describe the growth of AAS use as a 
public health concern in the UK (McVeigh and Begley, 2017). 
Paper 3 Large international online survey to identify extent of service engagement within a 
sub population of AAS users globally (Zahnow et al., 2017). 
Paper 4  A netnographic qualitative study of knowledge, attitudes, motivations and risk 
taking behaviours of 2, 4-Dinitrophenol (DNP) users (McVeigh et al., 2016a).  
Paper 5 Interviews and questionnaires to identify the early indications of the emergence of 
AAS as a public health issue in Ireland (McVeigh et al., 2017b). 
Paper 6 Qualitative interviews to identify health risks and barriers to service engagement in 
the United Kingdom (Kimergard and McVeigh, 2014a).  
Paper 7 Cross-sectional bio-behavioural to identify prevalence of HIV, hepatitis B and C 
together with associated risk behaviours amongst AAS users (Hope et al., 2013c). 
Paper 8 Analysis of longitudinal needle and syringe programme data resulting in the 
identification of AAS use as a significant public health issue (McVeigh et al., 2003a). 
25 
 
3.2 Theoretical approach  
Throughout the papers comprising this portfolio of work, various forms of literature from 
diverse disciplines have been accessed and read to inform a variety of methodologies and 
analytical strategies. Therefore there has not been adherence to a specific or uniform 
theoretical perspective or framework. However, in compiling this portfolio of work, re-
examining and summarising the work and drawing conclusions as to its implications and 
impact, a number of theories appear relevant to different aspects of these studies. A robust 
theoretical grounding will be essential if the development of effective policies and 
interventions for users of AAS and associated drugs are to be effective and successful. The 
work of Tim Rhodes in relation to risk environments and psychoactive drug users is 
particularly pertinent to this work (Rhodes, 2009, Rhodes, 2002, Kimergard and McVeigh, 
2014a). Rhodes highlights the relationship between physical, social, economic and policy 
factors and how it is the interplay of these factors that influence risk and the chances of 
harm occurring. These environmental factors have been applied to the use of AAS 
(Kimergard and McVeigh, 2014a) and further developed as a model to demonstrate a 
sociological framework for understanding AAS use (Bates et al., 2018). Similarly a 
socioecological framework has been proposed in relation to AAS use in sport. The 
‘dopogenic’ environment (Backhouse et al., 2017) highlights the need for a ‘whole-systems 
approach’ , with a focus on the interactions between individuals, their social networks and 
the influencing structures. It is essential that the influences that dictate behaviour and risk 
are fully appreciated if any intervention, such as those outlined Institute of Medicine Model 
of prevention (from “universal” to “aftercare”) (Warner and Boat, 2009) (Backhouse et al., 
2014) are to be evaluated (UNODC, 2015) and found to be effective. 
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While Rhodes is perhaps the key theoretical stance in relation to risk behaviours and harms, 
the work of Rogers and the theory of diffusion (Rogers, 1983, Rogers, 1995), contributes to 
our understanding of the changing epidemiology of AAS and associated drugs and is key to 
this portfolio of work. While by no means a new theory (De Tarde, 1903), it has adapted 
over time and been influenced by research into mass communication in the 1950s (Katz et 
al., 2017). The model features a structure by which a “trickle down” effect accelerates as 
knowledge, attitudes and behaviours are passed from a small group of innovators, to a 
larger group of early adopters to the (early and late) majority) and finally the 
“laggards”(Rogers, 1983) . In relation to drug use trends and behaviours, Zinberg’s 
influential contemporary work of the 1980s (Zinberg, 1984) played a part in its application 
to the field of substance use. The relevance of the theory of diffusion to “new” trends and 
patterns of drug use was illustrated Rogers’ “Diffusion of Innovation” (1983) and has been 
applied to inner city trends of the United States (Golub et al., 2005). The theory has also 
been explored and applied to the UK’s phenomenon of Novel Psychoactive Substances 
(NPS) (Sumnall et al., 2011), within a sophisticated online society(Corazza et al., 2017, 
Schifano et al., 2010) . Diffusion theory provides a useful framework for our understanding 
of changes in IPED use, and in particular AAS use, during recent decades. On a macro scale, 
the ‘innovators’ and ‘early adopters’ correspond to users in the United States, the ‘late 
adopters’ in the UK’ and the ‘laggards’ to the Republic of Ireland. On a Micro scale, the 
theory accounts for the diffusion from the city centre to the suburban and finally the rural 
geographical areas. The theory, in part, provides an explanation of how beliefs and 
behaviours can change and how the influence of a relatively small number of people (for 
example, (Phillips, 1991, Duchaine, 1989, Llewellyn, 2017)) can be so significant and 
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supports our understanding of changes in prevalence, practices and the illicit market of AAS 
and associated drugs. 
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Section 4: Changes in extent, characteristics and practices of AAS 
users 
 
Submitted papers 
 
1) Zahnow, R., McVeigh, J., Bates, G., Hope, V., Kean, J., Campbell, J. & Smith, J. (2018) 
Identifying a typology of men who use anabolic androgenic steroids (AAS). Int J Drug Policy, 
55, 105-112. 
 
2) McVeigh, J., & Begley, E. (2017). Anabolic steroids in the UK: an increasing issue for public 
health. Drugs: Education, Prevention and Policy, 24.:3, 278-285. 
 
4) McVeigh, J., Germain, J., & Van Hout, M. C. (2016). 2,4-Dinitrophenol, the inferno drug: a 
netnographic study of user experiences in the quest for leanness. Journal of Substance Use, 
22(2), 131-138. 
 
7) Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., Croxford 
S., Beynon C. M., Parry J. V., Bellis, M. A. & Ncube F. (2013).  Prevalence of, and risk factors 
for, HIV, hepatitis B and C infections among men who inject image and performance 
enhancing drugs: a cross-sectional study. BMJ OPEN, 3(9), 11 pages. 
 
8) McVeigh, J., Beynon, C., & Bellis, M. A. (2003). New challenges for agency based syringe 
exchange schemes: Analysis of 11 years of data (1991-2001) in Merseyside and Cheshire, 
United Kingdom. International Journal of Drug Policy, 14(5-6), 399-405. 
 
Supporting evidence 
 
Sagoe, D., McVeigh, J., Bjornebekk, A., Essilfie, M. S., Andreassen, C. S., & Pallesen, S. (2015). 
Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis. 
Substance abuse Treatment Prevention and Policy, 10, 19 pages. 
 
Stensballe, A., McVeigh, J., Breindahl, T., & Kimergard, A. (2015) Synthetic Growth Hormone 
releasers detected in seized drugs: New trends in the use of performance enhancement. 
Addiction, 110(2), 368-369. 
 
Evans-Brown, M., Kimergard, A., McVeigh, J., Chandler, M., & Brandt, S. D. (2014). 
Bodybuilding Supplements: Is the breast cancer drug tamoxifen being sold as a bodybuilding 
dietary supplement?. BMJ-British Medical Journal, 348, 2 pages. 
 
Evans-Brown, M., McVeigh, J., Perkins, C., & Bellis, M. A. (2012). Human Enhancement Drugs 
- The Emerging Challenges to Public Health: Human Enhancement Drugs - The Emerging 
Challenges to Public Health. Liverpool:  Liverpool John Moores University. 
 
Evans-Brown, M., Dawson, R. T., Chandler, M., & McVeigh, J. (2009). Use of melanotan I and 
II in the general population. British Medical Journal, 338. 
 
Evans-Brown, M., & McVeigh, J. (2009) Injecting human growth hormone as a performance-
enhancing drug-perspectives from the United Kingdom. Journal of Substance Use 14(5):267-
288. 
 
 
29 
 
 
As described in the introduction, there are a number of methodological barriers to ascertain 
an accurate estimate of the prevalence of AAS use. Historically, prevalence research in the 
UK has been restricted to specific populations, for example, those attending gymnasia 
(Korkia and Stimson, 1997, Lenehan et al., 1996) or self-identified as gay men (Bolding et al., 
2002). General population surveys have been subject to the bias and limitations of 
household surveys (ACMD, 2010b, Evans-Brown and McVeigh, 2009a), and the examination 
of motivations for use, relied mainly on small samples from the 1990s (Monaghan, 2002).  
 
Aims  
To identify and quantify the changes in extent, characteristics and practices of anabolic 
androgenic steroid users 
 
Contextualise the potential implications for public health related to any significant changes 
in the use of anabolic steroids and associated drugs.  
 
Contribution to evidence and understanding 
 Significant increases in the number of AAS injectors engaging with NSP services 
across the United Kingdom. 
 Identification of significant population of AAS users who do not inject and are not 
engaged with any health related services. 
 Diffusion of use from central urban post-industrial cities to suburban and rural areas. 
 Broadening population of use including older users due to cohort effect and later 
onset of use. 
 More diverse motivations for use, typology of user and risk profile. 
 Identification of significant concurrent use of psychoactive drugs and minority of 
prior injection of psychoactive drugs as a United Kingdom and a global phenomenon 
 Increasing prevalence of human growth hormone use amongst the AAS using 
population. 
 Adoption of drug regimens to incorporate a range of new peptide hormones 
including melanotan, MGF and GHRP-6. 
 Re-emergence of 2, 4-Dinitrophenol (DNP) amongst AAS users and its diffusion to the 
wider population 
 The identification of increased dosages, longer cycles and the introduction of “blast & 
cruise” regimens.    
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The following section draws on my portfolio of work which has increased our knowledge 
and depth of understanding of the complexities related to AAS use. It also summarises the 
evidence of change in relation to drugs of use and associated practices within the 
populations of individuals using AAS. 
 
4.1 The extent of anabolic androgenic steroid use 
 
 
While the UK Government has grown to rely on the Crime Survey for England and Wales for 
information relating to the prevalence  of illicit drug use (Broadfield, 2017), concerns 
regarding its reliability have been raised (Evans-brown and McVeigh, 2008, McVeigh and 
Evans-brown, 2009, Chandler and McVeigh, 2014, McVeigh et al., 2012a) and broadly 
accepted within policy (ACMD, 2010b). The main indicator of the extent and change over 
time of AAS use in the UK are data collected from NSPs (ACMD, 2010b). Finding presented in 
the papers comprising this portfolio of research are unique in that they originate from the 
only longitudinal dataset of its kind, comprising intelligence from harm reduction services in 
Cheshire and Merseyside in the UK from 1991 (Whitfield et al., 2017, Birtles, 1998, 
Chandler, 2009, Chandler and McVeigh, 2014, McVeigh and Begley, 2017, McVeigh et al., 
2003a).  McVeigh et al. 2003, identified a significant increase in new users of AAS presenting 
to services (P<0.001) over eleven years. Between 1991 and 2006, across the same 
geographical area, there was a 2,000% increase in AAS using clients (Evans-Brown and 
McVeigh, 2009a).  Further analyses in 2017 indicated a continuing trend, with a 342% 
increase in the number of individual AAS users accessing services in Cheshire and 
Merseyside and now accounting for 55% of clients (McVeigh and Begley, 2017). These 
analyses do not include numbers of individuals purchasing equipment online, a practice 
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which appears to be increasing in prevalence (McVeigh, 2017b, McVeigh, 2018a, McVeigh, 
2018b, McVeigh et al., 2015a). 
 
These data cannot distinguish between a change in prevalence of AAS use and a potential 
increase in the proportion of users accessing needle and syringe programmes. Equally, these 
do not take into account the proportion of individuals who are only using AAS orally. This 
remains largely unknown but data from the most recent national IPED survey indicated that 
over a quarter of users of AAS and associated drugs, use oral products only (Begley et al., 
2017). This indicates a potentially under-researched and under-served population. However, 
high quality NSP data do provide a valuable indication of the extent of use, particularly in 
the context of many service users purporting to access equipment for their peers (McVeigh, 
2007, McVeigh et al., 2003a). Even with these caveats the NSP data analysed for this 
portfolio of work represented a unique and major contribution to the only global 
epidemiological study of AAS use (Sagoe et al., 2014c). Furthermore, three UK Government 
reviews of AAS legislation (ACMD, 2010b) and three sets of National Institute of Health and 
Care Excellence (NICE) Guidelines  (Bates et al., 2013, McVeigh, 2017d, NICE, 2009) were 
informed by these findings.. 
 
4.2 Characteristics of users 
 
It is essential that consideration is given to the groups or types of users alongside any 
investigation into the extent of use. As identified in the introduction, work by this author 
and others during the 1990s in the UK identified aspiring or recreational bodybuilders as the 
main group of AAS users, with the primary motivation of increasing musculature (Korkia and 
Stimson, 1993, Lenehan et al., 1996, Perry et al., 1992, Williamson, 1991, Burton, 1996, 
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Monaghan, 1999). The advent and expansion of the internet, enhanced availability of retail,  
transportation and communication around AAS, together with low-cost pharmaceutical 
manufacture in countries such as China and India, contributed to the proliferation of 
lifestyle or human enhancement drugs (McVeigh et al., 2012b, Evans-Brown et al., 2012). 
This has supported a surge in consumer interest and new markets with varied motivations 
for use (Begley et al., 2017, McVeigh et al., 2015a). This trend can be observed in the recent 
national IPED survey results, indicating that for 6.5% and 7.8% of the sample of 684 AAS 
users interviewed, maintaining a youthful appearance or using as a form of self-directed  
hormone replacement therapy, respectively, was extremely important (Begley et al., 2017). 
A key issue associated with these drivers is around the age of users of AAS. Much of the 
research around this topic has looked at young people’s use, as has the policy and 
legislation focus (ACMD, 2010b, NICE, 2017). In contrast, research submitted as part of this 
portfolio does not support this premise (McVeigh and Begley, 2017). Both the mean and 
median age of AAS using client has increased from 26 to 31 years and 25 to 30 years 
respectively between 1995 and 2015. So, whilst most AAS users are aged between 20 and 
29, an increasing proportion are in the older categories, in part due to older users 
commencing use and partly attributed to an ageing cohort effect (McVeigh and Begley, 
2017).  
 
Building on the rudimentary classifications of AAS users of the 1990s (Dawson, 2001, 
Lenehan and McVeigh, 1998), work was undertaken to develop a more sophisticated 
understanding of AAS in the 21st century (Christiansen et al., 2016). Utilising previously 
collected qualitative interview data and supplemented by the observations of the authors, 
four ideal types of users were identified based on the effectiveness of AAS use and 
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associated risks: the Expert type, the Well-being type, the YOLO type and the Athlete.  Using 
the data collected for the National IPED study (Bates and McVeigh, 2016) and working with 
colleagues in the UK and Australia, detailed cluster analyses and logistic regression were 
conducted and published (Zahnow et al., 2018).  Findings reflected the four categories 
hypothesised by Christiansen et al., (2016), Cluster 1 (comprising 11.1% of the sample) were 
younger and motivated by fat loss; Cluster 2 (38.6%) were concerned with getting fit; 
Cluster 3 (25.4%) were motivated by muscle and strength gains; Cluster 4 (24.9%) were 
focused on specific goals (Zahnow et al., 2018). There were several noticeable differences in 
finding, such as the relative size of clusters/typologies and experiences of adverse effects. 
This may be explained by differences in characteristics of the samples caused by the specific 
recruitment strategies and also by methodologies and sample sizes of the two studies, 
however both studies identified structures of sub groups with implications for harm 
reduction and wider public health.  
 
This is little evidence related to AAS and socioeconomic group or association with 
deprivation. However, the rise of AAS use in the UK was first identified in the industrial, 
economically-challenged heartlands of the UK, in particular in the North of England 
(Lenehan et al., 1996, Best and Midgley, 1998) and South Wales (Korkia and Stimson, 1993, 
Perry et al., 1992, Perry and Littlepage, 1992). Analysis of NSP data illustrated the increasing 
numbers of AAS injectors presenting to Cheshire and Merseyside services in the North of 
England between 1991 and 2001 (McVeigh et al., 2003a). A survey of NSPs in towns and 
cities in North of England illustrated the preponderance of AAS users in these services 
(Kimergard and McVeigh, 2014c). Furthermore, this paper illustrates the diffusion of high 
levels of AAS use from the urban centre of Liverpool to the more affluent surrounding 
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suburban/rural areas over time (McVeigh and Begley, 2017), an effect previously reported 
within this geography for other forms of drug use (McVeigh et al., 2003b) and a well-
established theory of behaviour influence and change (Rogers, 1983). 
 
 
4.3 Changes in practice and usage 
 
While polypharmacy is not a new phenomenon amongst AAS users in the UK (Lenehan et 
al., 1996, Korkia and Stimson, 1997, McBride et al., 1996, Brennan et al., 2011, Rich et al., 
1998b), there are now an unprecedented array of substances used by this population. The 
use of human growth hormone has increased from 2.7% reported in 1993 (Korkia and 
Stimson, 1993) to 32% in 2013 (Hope et al., 2013c). Melanotan, an injectable melanocortin 
receptor agonists used as a tanning agent was unknown during the 1990s. In the mid-2000s, 
data from NSP in the UK indicated a small number of competitive bodybuilders injecting 
melanotan I and melanotan II in addition to AAS and a range of other substances (Evans-
Brown et al., 2009a). By 2013, 8.6%  of image and performance enhancing drug users were 
reporting the injection of melanotan (Hope et al., 2013c), rising to 13% in 2016 (Begley et 
al., 2017). Peptide hormones are now part of the repertoire of drugs used by many AAS 
users (Kimergard et al., 2014b) in particular growth hormone releasing hormones 
(Stensballe et al., 2015) including CJC 1295 (Van Hout and Hearne, 2016) and mechano 
growth factor (Esposito et al., 2012) alongside more established hormones such as insulin 
(Rich et al., 1998b) and insulin-like growth factor 1 (Begley et al., 2017). Increasingly post 
cycle therapy is utilised between cycles of AAS in an attempt to maintain the muscular gains, 
avoid reduction of libido and the lowering of mood. These effects are as a result exogenous 
testosterone’s effect on hypothalamic–pituitary–testicular (HPT) axis, resulting in the 
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suppression of endogenous testosterone production (Griffiths et al., 2016). Dosages, timing, 
and specific testosterone stimulating drugs, including human chorionic gonadotrophic 
(Hope et al., 2013c) in combination with anti-oestrogens such as clomiphene and tamoxifen 
(McVeigh et al., 2015a) are largely due to self-experimentation “I know personally when my 
body requires hCG..” (Kimergard and McVeigh, 2014a) and are widely promoted as 
‘responsible’ AAS usage (Scally and Tan, 2009, Llewellyn, 2017). 
 
2,4-Dinitrophenol (DNP), is another component of the AAS users pharmacopeia, although it 
is not licensed for human consumption and classed as a metabolic poison (Evans-Brown et 
al., 2012). DNP has gained increasing media attention3  and public health concern in recent 
years (Green et al., 2016, Hoxha and Petroczi, 2015). Although discovered 100 years ago 
(Koch et al., 1935, Tainter et al., 1934), its use has emerged sporadically as a potent weight 
loss agent (Grundlingh et al., 2011), particularly within bodybuilding cultures (Duchaine, 
1989, Llewellyn, 2017). Since 2010, the use has moved from AAS users to the wider 
population resulting in a number of high profile fatalities. In a survey led by McVeigh in 
2013, 8% of AAS users reported the use of DNP (McVeigh et al., 2015a), triggering the 
netnographic study submitted as part of this portfolio of work (McVeigh et al., 2016a). The 
study, the first of its kind to investigate this topic via online public websites, highlighted a 
dynamic web based market and identified the need to engage with influential website 
moderators to promote health messages and harm reduction amongst users and potential 
users of DNP (McVeigh et al., 2016a). The online methodology also contributed to the 
growing body of work utilizing the Kozinets’ netnographic approach (Kozinets, 2013) within 
                                                     
3 Particularly in newsprint in both Ireland eg Irish Times and the United Kingdom eg the Sunday Telegraph and 
the Daily Mail. 
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the field of illicit drug use including enhancement drugs (Bruneel et al., 2014, Germain et al., 
2017, Loi et al., 2017, Van Hout and Hearne, 2016, McVeigh et al., 2017a). 
 
Sagoe, McVeigh and colleagues identified an increasing array of image and performance 
enhancing drugs (IPEDs), and drugs used to combat side effects (Sagoe et al., 2015a, 
Zahnow et al., 2017). A recent survey of IPED users identified high levels the use of analgesic 
products in the previous year, both prescribed (25%) and over the counter (42%) (Begley et 
al., 2017). Furthermore, sports and nutritional supplements are commonly used (Llewellyn, 
2011) and associated with an increased propensity towards the use of illicit substances 
(Backhouse et al., 2013),  furthermore work co-authored by McVeigh identified that 
adulteration of nutritional supplements with classical AAS was relatively common (Abbate 
et al., 2015). The cancer treatment drug tamoxifen citrate was also identified ‘hidden in 
plain sight’ as a supplement to combat gynaecomastia (Evans-Brown et al., 2014).  
 
The Global Drug Survey, the largest drugs research project, collected data on 89,509 
individuals during a three month period in 2014/15 (GDS, 2015). The survey, in 11 
languages, primarily developed to recruit psychoactive drug users, in particular those using 
‘dance drugs’ (Barratt et al., 2014, Winstock et al., 2015). However, a module of questions 
related to IPEDs was developed by McVeigh and introduced to the survey, resulting in data 
on 1,000 males reporting the use of AAS (Zahnow et al., 2017). This sub group of AAS users 
resided in Europe, North America, South America, Asia, Africa and Australasia. While unable 
to indicate prevalence, it illustrated that AAS use amongst psychoactive drug users occurred 
regardless of legislation or cultural norms.  
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Recent work has also demonstrated the concerning levels of psychoactive drug use amongst 
anabolic androgenic steroid users (McVeigh et al., 2015a, Sagoe et al., 2015a), with cocaine 
used in the last year at 46% (Hope et al., 2013c) and lifetime prevalence of 51% (McVeigh et 
al., 2015a). These levels were unprecedented in the 1990s with cocaine use at 12% in the 
previous  six months (Lenehan et al., 1996), however even at these relatively low levels they 
were identified as a public health concern (Lenehan and McVeigh, 1998).  
 
Despite the difficulties in assessing dosages of drugs being used, due to the illicit nature of 
the market (Evans-Brown et al., 2009b), self-reported dosages of AAS are significantly higher 
than those used in the 1990s (Evans-Brown et al., 2012), even amongst novice users, 
(Chandler, 2013, McVeigh and Begley, 2017).  The length of cycle (the period that drugs are 
used) has also increased, including one study indicating a quarter of users utilizing ‘blast and 
cruise’. This was the first academic report of a phenomenon where the ‘off cycle’ is replaced 
with a period of lower dosage (but still in the range that is several times higher than normal 
endogenous production) (Chandler, 2013, McVeigh and Begley, 2017), and has implications 
for health and recovery. 
 
4.4 Conclusion 
 
The published papers and supporting public health reports within my portfolio of research 
highlight the dynamic nature of AAS use and other associated IPEDs. We have significant 
evidence of increases in the numbers of AAS users in the UK (McVeigh and Begley, 2017, 
McVeigh et al., 2003a), changes in the demographics and types of users (Zahnow et al., 
2018, Begley et al., 2017), new (Evans-Brown and McVeigh, 2009b, Evans-Brown et al., 
2009a) and re-emerging drugs of use (McVeigh et al., 2016a), and changes in specific 
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practices (McVeigh and Begley, 2017, McVeigh et al., 2015a). All these factors contribute to 
the growing public health concern regarding this issues, the need for greater understanding 
of the phenomenon, and timely policy responses (Evans-Brown et al., 2012, McVeigh et al., 
2012b). 
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Section 5: Evidence of harm related to the use of AAS and associated 
drugs  
 
 
Submitted papers 
 
McVeigh, J., & Begley, E. (2017). Anabolic steroids in the UK: an increasing issue for public 
health. Drugs: Education, Prevention and Policy, 24:3, 278-285. 
 
Zahnow, R., McVeigh, J., Ferris, J., & Winstock, A. (2017). Adverse effects, health service 
engagement, and service satisfaction among anabolic androgenic steroid users. 
Contemporary Drug Problems 44(1):69-83 01  
 
Kimergard, A., & McVeigh, J. (2014). Environments, risk and health harms: a qualitative 
investigation into the illicit use of anabolic steroids among people using harm reduction 
services in the UK. BMJ Open, 4(6), 7 pages. 
 
Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., Croxford 
S., Beynon C. M., Parry J. V., Bellis, M. A. & Ncube F. (2013).  Prevalence of, and risk factors 
for, HIV, hepatitis B and C infections among men who inject image and performance 
enhancing drugs: a cross-sectional study. BMJ OPEN, 3(9), 11 pages. 
 
Supporting evidence 
 
Hope, VD, McVeigh, J Smith, J. Glass, R, Njoroge, J, Tanner, C, Parry, JV, Ncube, F, Desai M 
(2017) Low levels of hepatitis C diagnosis and testing uptake among people who inject 
image and performance enhancing drugs in England and Wales, 2012-15 Drug and Alcohol 
Dependence Volume 179, Pages 83–86 
 
Evans-Brown, M., McVeigh, J., Perkins, C., & Bellis, M. A. (2012). Human Enhancement 
Drugs - The Emerging Challenges to Public Health: Human Enhancement Drugs - The 
Emerging Challenges to Public Health. Liverpool: Centre for Public Health, Liverpool John 
Moores University. 
 
Hope, V. D., Harris, R., McVeigh, J., Cullen, K. J., Smith, J., Parry, J. V., . . . Ncube, F. (2016). 
Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance 
Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 
1992-2013. JAIDS-Journal of Acquired Immune Deficiency Syndrome, 71(3), 331-337. 
 
Breindahl, T., Evans-Brown, M., Hindersson, P., McVeigh, J., Bellis, M., Stensballe, A., & 
Kimergard, A. (2015). Identification and characterization by LC-UV-MS/MS of melanotan II 
skin-tanning products sold illegally on the Internet. Drug Testing and Analysis, 7(2), 164-172. 
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As described in the introduction (Section 2), by the conclusion of the twentieth century, the 
scientific and medical community had a comprehensive understanding of the 
pharmacological and physiological mechanisms which may contribute to adverse 
consequences for the AAS user (Kopera, 1993, Kicman, 2008a). However, the harms 
associated with the use of these substances are far from limited to their pharmacological 
effects. 
Aims  
To identify the potential extent of previously unrecognised or under recognised health risks 
associated with the use of anabolic androgenic steroids and associated drugs. 
 
 
Contribution to evidence and understanding 
 Confirmation of established harms through systematic review. 
 The first identification and confirmation of a significant number of HIV positive users 
of AAS in the United Kingdom.  
 Hepatitis B and hepatitis C prevalence significantly higher amongst AAS users than 
the general population. 
 Low levels of hepatitis c testing and diagnosis amongst AAS using population.  
 Identification of risk and predictive factors for blood borne virus infection amongst 
AAS users, including previous psychoactive drug use, sex between men and 
imprisonment. 
 High blood borne virus transmission risk behaviours amongst some populations of 
AAS users, including sharing of injecting equipment and high levels of unprotected 
sex.  
 Significant levels of localised infection such as abscess formation and soft tissue 
injury. 
 Specific cases relating to unexpected adverse effects of drugs due to adulteration and 
substitution of active pharmaceutical ingredients. 
 The extent of variation in strength of illicitly manufactured AAS and associated drugs. 
 The extent of hidden AAS and associated drugs within supplements purchased online 
and in high street shops. 
 The ease of availability and low levels of knowledge related to high risk substances 
such as  2,4-Dinitrophenol (DNP). 
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The contribution of research submitted for this portfolio of work can best be described 
within the categories of blood borne viruses (BBV) and injecting injuries, adulterated and 
contaminated products and drugs used in combination with AAS. 
 
5.1 Established adverse effects of AAS. 
 
Recent years have seen the publication of the most comprehensive overview of adverse 
effects by the Endocrine Society (Pope et al., 2014b). The Scientific Statement categorises 
the types of harms, such as chronic  and acute (Strauss et al., 1985) physical harms (Friedle, 
1993) psychological harm (Bahrke et al., 1996) and dependence  (Brower et al., 1991a, 
Brower, 2002). One of the main areas of increased understanding of these adverse effects 
are in relation ‘anabolic androgenic steroid induced hypogonadism’ (Tan and Scally, 2009, 
Kanayama et al., 2015), particularly in those with sustained use (McVeigh et al., 2015a, 
Jones et al., 2011)  and in the longer term cardiovascular risks have become the main area 
of investigation (Baggish et al., 2017, Baggish et al., 2010). However, an area of increasing 
recognition and concern is in relation to the effects of AAS on the brain. There is emerging 
evidence suggesting that prolonged AAS use is associated with cognitive impairments 
including memory visuospatial abilities (Heffernan et al., 2015, Grogan et al., 2006, 
Kanayama et al., 2013, Kaufman et al., 2015). These impairments have been explained by 
changes in the structure and connectivity of the brain (Bjornebekk et al., 2017, Westlye et 
al., 2017). 
 
 
5.2  Adverse effects associated with injecting behaviours  
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5.2.1 HIV, hepatitis B and hepatitis C 
 
 The issue of BBV transmission and injecting injuries remained largely unrecognised amongst 
academics or within the AAS user communities in the United States (Yesalis et al., 1993, 
Phillips, 1991, Duchaine, 1989). In the UK, reliable UK data were sparse, with only a small 
published surveillance study of 149 AAS injectors indicating the presence of hepatitis B core 
antigen in 2% of the sample and no evidence of HIV (Crampin et al., 1998).  A small number 
of academics and practitioners in the UK, continued to highlight the potential transmission 
of BBV amongst this population as a public health concern (Dawson, 2001, Morrison, 1994, 
Lenehan and McVeigh, 1994, Best and Midgley, 1998, Midgley et al., 2000). The public 
health issue regarding the transmission of BBV was also disputed between academics in 
Australia (Iversen et al., 2013, Day et al., 2008). However, it wasn’t until the publication of 
the first large-scale cross-sectional study of BBV transmission in 2013, that the extent of the 
public health issue was recognised (Hope et al., 2013c). This ground breaking paper was the 
first to identify that the prevalence of HIV amongst injectors of AAS (and other IPEDs was 
similar to that of injectors of psychoactive drugs (Bates et al., 2017b, Iversen et al., 2016, 
Kean, 2014, McVeigh, 2017d, McVeigh and Begley, 2017, McVeigh et al., 2015a). 
Furthermore, prevalence of hepatitis B and hepatitis C were identified as public health 
concerns with hepatitis C at ten times that found in the general population(Hope et al., 
2017). Whilst individual cases of viral hepatitis were identified amongst injectors of AAS 
(Rich et al., 1998a, Crampin et al., 1998), the work of Hope, McVeigh and colleagues was the 
first to quantify the prevalence of infection within this population. These findings have had a 
significant impact on UK policy and guidelines issued by Public Health England Department 
of Health and the National Institute for Health and Care Excellence (NICE) (PHE, 2014, 
Department of Health, 2017, NICE, 2017). Further analysis illustrated that HIV had been 
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present within this population for some time and was increasing, with needle sharing, 
although lower than in those injecting psychoactive drugs (Larance et al., 2008, Hope et al., 
2013c, Delalande et al., 1998, HPA et al., 2012) and low uptake of condoms considered to be 
key factors (Hope et al., 2016). Further issues such as increased libido caused by AAS, 
concomitant use of cocaine and sildenafil (and associated drugs that may increase libido) 
and higher levels of AAS use amongst men who have sex with men have all been highlighted 
as areas of concerning regarding the prevention of BBV transmission (Bates et al., 2017b, 
Evans-Brown and McVeigh, 2009a, McVeigh and Begley, 2017, McVeigh et al., 2012a). 
Previous injection of a psychoactive drug and incarceration in prison have also been 
identified as predictive factors of BBV infection (Hope et al., 2013c, McVeigh, 2017c, 
McVeigh, 2018a) 
 
5.2.2 Injection site injuries and infections 
 
Evidence related to localised infections and other problems associated with injecting are 
largely restricted to individual case reports (Larance et al., 2008, Dickinson and Rich, 1996, 
Rich et al., 1999a, Rich et al., 1999b, Aitken et al., 2002, Delalande et al., 1998, Driscoll et al., 
2011). While levels of injuries and infections amongst people who inject psychoactive drugs 
was well established (HPA et al., 2012), this was not the case for those injecting AAS and 
associated drugs (Evans-Brown et al., 2012, McVeigh et al., 2012a). Furthermore, while a 
growing number of case reports linked to the injection of AAS have been published, few 
cases related to other image and performance enhancing drugs have been identified or 
reported (Brennan et al., 2016, Bates et al., 2013, Hope et al., 2013c, Evans-Brown et al., 
2012, McVeigh, 2018b, McVeigh et al., 2012a). Research by McVeigh and colleagues 
resulted in levels of local infection and injury being identified and reported in 2014, 
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indicating a further emerging public health issue amongst this population (Hope et al., 2010, 
Hope et al., 2015). Nearly half (42%) of the sample of the 366 male users of AAS reporting 
redness, swelling and tenderness following injection of AAS or other IPEDs and over a third 
(36%) in the previous year. Levels of infection were lower than that observed amongst 
people who inject psychoactive drugs, the 7% reporting an abscess or open wound (in some 
cases multiple episodes) constitutes a significant health impact and potential burden on 
healthcare. Furthermore, this sample comprised male IPED injectors engaged with NSPs, 
those who are not in contact with services may be engaging in a myriad of risk behaviours 
and experiencing harms at much higher levels. 
 
5.3  Harms associated with adulterated and contaminated AAS and associated 
drugs 
 
Counterfeit and adulterated pharmaceuticals are not restricted to AAS and other IPEDs but 
are a global public health concern (Fernandez et al., 2011, Tomic et al., 2010, Bonati, 2009, 
Pang, 2008, Cole et al., 2011, Evans-Brown et al., 2012) 
  
The issue of adulterated AAS (a term comprising fake, contaminated, counterfeit and 
unlicensed products) is a long standing issue affecting user groups (Duchaine, 1989), 
identified as a concern amongst academics and the AAS community (Coomber et al., 2014, 
Cordaro et al., 2011, McVeigh and Lenehan, 1994, Perry, 1995, Abbate et al., 2015, Lenehan 
and McVeigh, 1998, McVeigh, 1996, Kimergard and McVeigh, 2014a, Graham et al., 2009, 
Musshoff et al., 1997, Grunding and Bachmann, 1995, Llewellyn and Tober, 2010, Cohen et 
al., 2007).  In 2009, McVeigh and colleagues published a summary of the health implications 
of adulterated AAS and also highlighted the confounding effect of the issue on the 
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identification of the health harms of these drugs (Evans-Brown et al., 2009b). This led to a 
series of studies, both reactive, in an attempt to identify the cause of adverse events or 
concerns  (Evans-Brown et al., 2014, Kimergard et al., 2014a, Kimergard et al., 2014b, 
Stensballe et al., 2015) and in sampling to ascertain the prevalence and extent of 
adulteration within the market (Abbate et al., 2015, Breindahl et al., 2015). The public 
health implications of this issue are a direct result of the illicit market with the majority of 
products being manufactured outside any regulation or quality assurance (McVeigh and 
Begley, 2017, ACMD, 2010b). The danger of accidental substitution and the potential for 
harm was illustrated in an investigation into adverse effects reported by a bodybuilder who 
had been injecting what was purported to be the anabolic hormone GHRP-6. Following 
complaints of nausea, skin pigmentation and several other unexpected effects, the product 
was analysed with colleagues in Norway and Denmark and identified as melanotan II, an 
injectable tanning hormone (Kimergard et al., 2014a, Kimergard et al., 2014b).  
 
In a study of investigating the content and public health implications of the use of 
melanotan II, 73 specimens were purchased from three online retailers. Samples were all 
under strength, varying from 4mg to 9mg with some products containing up to 6% of 
unknown impurities (Breindahl et al., 2015). A total 24 samples of bodybuilding 
supplements were purchased from two fitness shops in Merseyside and three online 
retailers. Half of the products were identified as containing anabolic steroids controlled 
under the Misuse of Drugs Act (1971), at varying dosages (Abbate et al., 2015). This 
highlights the difficulties in attributing causality to individual drugs and even in the 
identification of control groups for research involving users of AAS (Evans-Brown et al., 
2009b, McVeigh and Begley, 2017).  
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2,4-Dinitrophenol (DNP), a potent weight loss product is not licensed for human 
consumption and is therefore not subject to any medicines control (Evans-Brown et al., 
2012). Online research illustrated the levels of risk associated with this toxic substance and 
how a lack of any quality assurance and administration literature can exacerbate such 
hazards (McVeigh et al., 2016a). The paper identified many online conversations focused on 
the unparalleled weight losses experienced through the use of DNP, with some discussions 
also featuring concerns regarding the potential for harm via uncontrolled hyperthermia. 
However, a common belief centred on an ability to limit the dangers through careful 
dosage:  
“Many people think this drug is very dangerous. . . and it is. . .if misused. . . basically, 
there is no upper-limit to how high your body-temperature can go on this stuff. . . 
which means your dosage really has to be watched closely.” 
However, even ‘experienced’ users appeared oblivious to the impossible task of managing a 
dosage of a toxic substance of unknown strength.  
5.4 Conclusion 
 
In recent years, significant progress has been made in identifying serious, chronic adverse 
effects associated with AAS, in particular those associated with the heart (Baggish et al., 
2017, Thiblin et al., 2015) and brain (Seitz et al., 2017, Westlye et al., 2017, Bjornebekk et 
al., 2017), together with a better understanding of the psychological impact of this form of 
drug use (Griffiths et al., 2018, Kanayama et al., 2018). However, research within this 
portfolio of work has made a significant contribution to our understanding of harms related 
to routes of administration of AAS and associated drugs, together with factors associated 
with the illicit market. Research by McVeigh and colleagues at Liverpool John Moores 
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University and other Institutions has identified a significant public health threat in relation 
to BBV (Hope et al., 2016, Hope et al., 2013c), in particular HIV (Bates et al., 2017b) and 
hepatitis C (Hope et al., 2017), as well as localised infections and soft tissue damage (Hope 
et al., 2015). In addition to written academic outputs, conferences targeting policy makers, 
practitioners and members of the AAS user communities have been an important vehicle for 
disseminating information relating to harms and risks both in the UK (McVeigh, 2017b, 
McVeigh, 2017e, McVeigh, 2018a) and internationally (McVeigh, 2017a, McVeigh, 2017c). 
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Section six: The health and drug policy response to the emerging 
public health issue. 
Submitted papers 
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services in the UK. BMJ Open, 4(6), 7 pages. 
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Bates, G., Jones, L., & McVeigh, J. (2013). Update of NICE Guidance PH18 on 'Needle and 
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effectiveness and cost-effectiveness of needle and syringe programmes for injecting 
drug users. 
49 
 
 
6.1 Health policy response to AAS use 
 
The UK responded quickly to the threat of an HIV epidemic amongst people who inject 
drugs (Stimson, 1995, Stimson, 1996), and adapted to the changing profile of drug users 
(McVeigh et al., 2003b), in particular the increase in AAS use from the early 1990s (McVeigh 
et al., 2003a), (McVeigh and Begley, 2017). Similarly to the UK harm reduction initiatives in 
the 1980s, interventions were established prior to central Government guidelines or 
Aims  
To identify the policy and practice response to the use of anabolic androgenic steroid use 
and associated drugs. 
 
To highlight the impact of policy, gaps in service provision and implications for public health. 
 
 
Contribution to evidence and understanding. 
 The United Kingdom’s extensive provision of needle and syringe programmes (NSPs) 
has changed significantly since the 1990s and is now engaged with large numbers of 
AAS injectors. 
 Policy and guidance related to optimal NSP service provision has been late and often 
poorly adhered to resulting in differences in service uptake and engagement across 
the United Kingdom.   
 Systematic reviews have confirmed the lack of evidence related to effectiveness of 
different interventions and engagement strategies with AAS users. 
 There is significant mistrust of academics and health service providers amongst 
populations of AAS users. 
 Low levels of generic health service uptake to treat harms associated with AAS use in 
the United Kingdom and globally. 
 Blood borne virus testing and vaccination remains low amongst AAS users. 
 A failure to recognise the extent and implications of emerging AAS use in Ireland is a 
significant public health concern. 
 Missed opportunity to effectively engage with populations of AAS through sexual 
health services. 
 Increasing health policy awareness of implications of AAS use in United Kingdom 
clinical guidelines. 
 Changes in United Kingdom legislation have not reduced prevalence of use and have 
had negative unintended health consequences on the illicit market. 
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recommendations (Stimson, 1995).  It was not until 2008 that guidelines on optimal 
provision of NSP was published. Initial systematic reviews and NICE recommendations and 
the subsequent publications provided a template for NSP service targeting those who inject 
AAS (Bates et al., 2013, Kean, 2014, McVeigh, 2017d, NICE, 2009, NICE, 2017, Jones, 2013, 
Jones et al., 2008, Jones et al., 2010). However, barriers to NSP service engagement 
persisted in parts of the UK (Kimergard and McVeigh, 2014c), with users of AAS respecting 
and adhering to peer advice rather than public health information (Kimergard and McVeigh, 
2014a). In the event of adverse  effects, AAS were as likely to self-treat (43%) or simply wait 
and hope that they  would resolve on their own (45%), as they would seek treatment from a 
health practitioner (McVeigh et al., 2015a). There remains scant evidence to support 
methods of health promotion, drug use prevention or harm reduction other than NSP, with 
robust effectiveness evaluations published (McVeigh and Begley, 2017, Backhouse et al., 
2014, Bates et al., 2017a). These conclusions were provided in expert testimony to NICE 
(McVeigh, 2017d) and incorporated into NICE guidelines (NICE, 2017). 
 
6.1.2 Response to BBV transmission in the UK and internationally 
 
Vaccination and treatment of BBV remains a major concern with less than a quarter of AAS 
injectors receiving any hepatitis B vaccination (Hope et al., 2013c, Begley et al., 2017). 
Hepatitis C, present in 5% of AAS injectors, remains undiagnosed in the majority of AAS 
injectors who had not injected a psychoactive drug. Uptake of viral screening was poor, with 
only 40% of AAS injectors having ever been tested for hepatitis C (Hope et al., 2017). In 
response to localised infections, only 17% sought medical assistance for redness tenderness 
and swelling. Although 76% of those who had experienced an abscess, or open wound at an 
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injection site presented to health services, nearly half (47%) had attended an accident and 
emergency clinic, and 26% had attempted self-treatment (Hope et al., 2015). 
 
Similarly to the UK, Ireland also lacks robust population level research into the use of AAS 
and associated drugs (Curtin et al., 2017). The All-Ireland drug prevalence survey  in 2010/11 
indicated the established use of AAS (lifetime prevalence of 2%), supporting the evidence of 
case reports (McElrath and Connolly, 2006) although prevalence was not recently reported 
by the Ireland Focal Point to the European Monitoring Centre for Drugs and Drug Addiction 
(National Advisory Committee on  Drugs, 2012, Curtin et al., 2017). Research published in 
Dublin 2014 highlighted a vibrant community of anabolic steroid users (Jennings et al., 
2014). An evaluation of needle and syringe provision (NSP) in Ireland indicated that anabolic 
steroid users constituted the second largest group of clients of needle and syringe 
programmes (Bates et al., 2015). Despite this and increasing numbers of reports on AAS use 
in the Irish media (Tuite, 2017, Darcy, 2016, O'Regan, 2017a, O'Regan, 2017b, Walsh, 2017, 
Jones, 2017), the issue, has to date,  received little policy or strategy attention in Ireland 
(Jennings et al., 2014). Following on from  the NSP evaluation (Bates et al., 2015), produced 
a qualitative paper on pharmacist experiences of NSP in Ireland (McVeigh et al., 2017b). 
Amongst the key implications for policy that were identified in the study, was the lack of a 
concerted public health response to injecting drug use, in particular the lack of targeted 
interventions for the relatively new cohort of people who inject AAS in Ireland (McVeigh et 
al., 2017b). 
 
6.1.3 Engagement and barriers 
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Building on earlier work in both in Australia (Larance et al., 2008) and UK (Kimergard and 
McVeigh, 2014c), data from the Global Drug Survey indicated that poor health service 
uptake by users of AAS was a global issue, with the vast majority (86%) believing that their 
doctor would not be willing to help them and a quarter believing that their general 
practitioner did not have the necessary knowledge to help them (Zahnow et al., 2017). Only 
a minority of those who had engaged with a General Practitioner in relation to their AAS 
reported that any discussion had taken place regarding mood or psychological wellbeing 
(33.8%). However, AAS users were more likely to present to health services if concerned 
about sexual function. This may provide some insight to how monitoring and treatment of 
health problems amongst AAS users could be targeted. 
 
6.1.4 The impact of changes in UK drugs legislation on the use of anabolic androgenic 
steroids  
 
Regardless of changes to the Misuse of Drugs Act (1971) in the UK in 1996, 2001 and 2010 
there remains no evidence of any positive impact on prevalence or associated harms of AAS 
use or other image and performance enhancing drugs (ACMD, 2010b, Corazza et al., 2014, 
Evans-Brown and McVeigh, 2009a, Evans-Brown et al., 2012, Lenehan and McVeigh, 1998, 
McVeigh, 1996, McVeigh, 2018b, McVeigh et al., 2012a). The biggest source of AAS and 
associated drugs remains the illicit market (Siva, 2010, Schnetzler et al., 2010, Eaton et al., 
2006, McVeigh et al., 2015a, McVeigh and Begley, 2017), furthermore, regardless of 
different forms of  legislation in different countries  (ACMD, 2010b, Denham, 2006, 
Kleinman and Petit, 1993, Yesalis et al., 1997) there remains little variation in prevalence of 
use (Sagoe et al., 2014c, Sagoe and Pallesen, 2018, Nakhaee et al., 2013, Santos et al., 2010, 
Buckley, 1988, Stubbe et al., 2014, Sagoe et al., 2015b, Bahri et al., 2017, Ip et al., 2017, 
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Pope et al., 2014a) or associated practices and harms (Sagoe et al., 2014a, Sagoe et al., 
2014b, Sagoe et al., 2015a, Zahnow et al., 2017, Diclemente, 2014, McVeigh et al., 2015a, 
Begley et al., 2017, McVeigh, 2017a, McVeigh, 2018a). 
 
6.2 Conclusions 
 
The UK has developed and adapted NSP to the needs of AAS injectors to varying degrees 
across the UK. Research by McVeigh and colleagues has had a significant influence over the 
last 20 years (McVeigh et al., 2003a, McVeigh and Begley, 2017), contributing to legislation 
(ACMD, 2010b), NICE guidelines (NICE, 2014, NICE, 2009, NICE, 2017), public health strategy 
(PHE, 2014) and clinical guidelines for the management of substance misuse (Department of 
Health, 2017). However, concerns raised in the 1990s regarding primary care provision to 
AAS users (McVeigh, 1996, Lenehan et al., 1996) continue in the UK (McVeigh et al., 2015a) 
and internationally (Zahnow et al., 2017). 
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Section 7: Reflection, conclusions and future direction 
 
During the period of this research I have matured from an enthusiastic, inexperienced 
researcher to a more informed and measured observer and commentator. While the 
influence of academic collaborators and role models should not be underestimated, the 
engagement with the AAS using communities and their acceptance of me, as a neutral 
outsider has been paramount.  
There has been significant progress over the last 25 years in the generation of new evidence 
and the increase in our understanding of many of the issues associated with AAS and 
associated drugs. We now have a much improved understanding of the scale of the issue 
(McVeigh, 2017c), although we still have no robust evidence as to the incidence nor 
prevalence (ACMD, 2010b, McVeigh et al., 2012a, McVeigh and Begley, 2017).  However, 
the foci of the research, the methodologies used, the reporting of findings and the 
conclusions and recommendations made, are all subject to potential bias. The issues related 
to HIV prevalence amongst users of AAS exemplifies the potential for bias, misinterpretation 
and the further withdrawal of an already hard to reach population. While the identification 
of an HIV prevalence of approximately 1% - 2% amongst those sampled in the United 
Kingdom is robust (Hope et al., 2016, Hope et al., 2013b), there is caution required when 
extrapolating these data across the whole population of people who use AAS and it is clearly 
not generalizable across all AAS using communities. While care was take within the cited 
papers to emphasize that transmission may have occurred through routes other than 
sharing injecting equipment used for AAS, for example, previous psychoactive injecting 
behaviour or sexual contact, individuals within some communities of AAS users responded 
negatively to these publications (Underwood, In press). Their response to what they 
believed was an inaccurate reflection of AAS injecting practices, created further barriers to 
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effective engagement with their communities.  We now recognise the heterogeneity of AAS 
users, the different typologies (Zahnow et al., 2018, Christiansen et al., 2016), together with 
both established and emerging subpopulations of users (Van Hout and Kean, 2015, 
Metastasio et al., 2018). We are starting to appreciate some of the often complex and multi-
faceted drivers and decision processes associated with this drug use (Boardley et al., 2014, 
Till et al., 2016). We now have a much improved appreciation of the practices of AAS drug 
use and associated risks. In particular, evidence from the national IPED studies (Bates and 
McVeigh, 2016, Begley et al., 2017, Chandler and McVeigh, 2014, McVeigh, 2017c) have 
identified the increasing array of available drugs (Evans-Brown and McVeigh, 2009b) and 
the growing trend of ‘blast and cruise’, which sees AAS users remain ‘on cycle’ without 
breaks. 
Adulterated AAS and associated drugs and their potential for harm is nothing new (McVeigh 
and Lenehan, 1994), however, academic outputs as part of this portfolio of research, 
illustrate both the extent and the public health implications of the issue (Evans-Brown et al., 
2009b, Kimergard et al., 2014b, Evans-Brown et al., 2014, Kimergard et al., 2014a, Breindahl 
et al., 2015).  
The public health significance of the identification of significant levels of HIV within the AAS 
using community (Hope et al., 2013c, Hope et al., 2016) cannot be lost although we clearly 
need a better understanding of transmission routes. This, together with evidence of 
undiagnosed hepatitis C, constitute a major concern for public health. The prevention of 
BBV transmission has been at the heart of the UK’s harm reduction strategy for many years. 
Research submitted as part of this portfolio of research has had a significant impact on 
health policy both in the UK and overseas. However, while BBV remains a public health 
priority within NSPs (Jones et al., 2010, Bates et al., 2013, Jones, 2013, Kimergard and 
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McVeigh, 2014b, McVeigh et al., 2015b, Iversen et al., 2016, McVeigh et al., 2016b, McVeigh 
and Begley, 2017), in relation to prevalence (Hope et al., 2013a, Hope et al., 2016) and 
associated risk behaviours (Hope et al., 2017, Glass et al., 2018) health professionals must 
be cognisant of the priorities and concerns of the individual AAS users (Kimergard and 
McVeigh, 2014b, Kimergard and McVeigh, 2014a, Kimergard, 2015), even if they considered 
to have a lower potential for harm (Hope et al., 2015).  
 
Large numbers of AAS users are accessing NSP services in parts of the North of England, 
Scotland and Wales (Kimergard and McVeigh, 2014c, Chandler and McVeigh, 2014, McVeigh 
et al., 2015a, Bates and McVeigh, 2016, McVeigh and Begley, 2017, Begley et al., 2017, 
McVeigh, 2018a). However, despite national guidance to the contrary, there remains no 
standard provision or evaluation of prevention or harm reduction (NICE, 2014, NICE, 2009, 
HM Government, 2017, Public Health England, 2015, Department of Health, 2017) 
interventions. 
 
The innovative substance use surveillance systems developed at the Public Health Institute 
under the direction of the author of this portfolio of work (Whitfield et al., 2017) have 
provided essential intelligence regarding service activity and outcomes of those using AAS 
(Chandler et al., 2009, McVeigh et al., 2003b). This unique longitudinal monitoring system of 
AAS service provision is the only source of robust trend data (McVeigh et al., 2003a, 
McVeigh and Begley, 2017). Qualitative research conducted by McVeigh and colleagues has 
identified significant barriers to the development of effective engagement and delivery of 
interventions in the UK (Kimergard and McVeigh, 2014a, Kimergard and McVeigh, 2014c). 
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Summary of contribution to evidence and understanding of AAS use 
 
Changes in extent, characteristics and practices of AAS users  
 Significant increases in the number of AAS injectors engaging with NSP across UK. 
 Health service gap for AAS users who do not inject  
 Diffusion of use from central urban post-industrial cities to suburban and rural areas. 
 Increased numbers of older AAS users due to cohort effect and later onset of use. 
 More diverse motivations for use, typology of user and risk profile. 
 High levels of psychoactive drug use amongst AAS users. 
 Population of AAS users who have previously injected psychoactive drugs. 
 Increasing prevalence of human growth hormone. 
 Increased use of new peptide hormones including melanotan, MGF and GHRP-6. 
 Re-emergence of DNP amongst AAS users and its diffusion to the wider population. 
 Increased dosages, longer cycles and the introduction of “blast & cruise” regimens.    
 
Evidence of harm related to the use of AAS and associated drugs 
 Confirmation of established harms through systematic review 
 Significant number of HIV positive users of AAS in the United Kingdom.  
 Hepatitis B and hepatitis C infection amongst AAS users. 
 Low levels of hepatitis c testing and diagnosis amongst AAS using population.  
 Psychoactive drug use, sex between men and imprisonment predictive of infection. 
 Sharing of injecting equipment amongst sub-populations of AAS users. 
 High levels of unprotected sex amongst AAS users. 
 Common localised infection such as abscess formation and soft tissue injury. 
 Adulteration and substitution of active ingredients resulting in harm. 
 Wide variation in strength of illicitly manufactured AAS and associated drugs. 
 Adulteration of supplements with AAS and associated drugs. 
 The ease of availability and low understanding of risks associated with DNP. 
 
The health and drug policy response to the emerging public health issue 
 NSPs in UK engaged with large numbers of AAS injectors. 
 Wide variation in NSP service uptake and engagement across the UK.   
 Little evidence of effectiveness of engagement strategies with AAS users. 
 Mistrust of academics and health service amongst many AAS users. 
 Reluctance of AAS users to declare use or seek treatment for harms. 
 Blood borne virus testing and vaccination remains low amongst AAS users. 
 Inadequate response to AAS use in Ireland. 
 Potential for greater engagement of AAS users via sexual health services. 
 Recognition of AAS use within UK clinical guidelines and drugs policy. 
 Legislation changes have not impacted on prevalence of AAS use. 
 Negative unintended health consequences of legislation. 
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Furthermore, work conducted in Ireland (Bates et al., 2015, McVeigh et al., 2017b), 
illustrated the situation in a country which has yet to respond to the public health 
challenges posed by AAS use. Findings from the (Zahnow et al., 2017) provide evidence of 
the issue impacting on regions around the world, with countries such as Brazil facing even 
greater challenges than the UK. The epidemiological complexity of AAS use is further 
highlighted at sub-population level, with the differing beliefs, practices and motivations for 
use of AAS amongst third generation South Asian men in the UK (Van Hout and Kean, 2015). 
 
Significant progress has been made over the last 25 years in relation to our understanding of 
AAS user populations, their characteristics and practices (Zahnow et al., 2018); the potential 
harms associated with use (Begley et al., 2017, Hope et al., 2017, Hope et al., 2016, Hope et 
al., 2013c, Hope et al., 2015, McVeigh et al., 2015a)  and the extent of interventions to 
prevent the transmission of BBV amongst AAS users (McVeigh and Begley, 2017, McVeigh et 
al., 2003a). However, there remains scant evidence relating to effective interventions to 
prevent the uptake of AAS (McVeigh, 2017d, Bates et al., 2017a); reduce harms and 
promote health amongst users (Bates et al., 2013, ACMD, 2010b, Evans-Brown and 
McVeigh, 2009a) and to support the cessation of use (Kanayama et al., 2010a). Where 
evidence of treatment or interventions for AAS users is available, it is largely confined to the 
symptomatic treatment of associated health harms (cardiovascular, hepatic, renal, sexual, 
behavioural and affective) rather than cessation or harm reduction.  
 
We remain at the early stages of recognising the complex and interrelated motivations and 
drivers of AAS use amongst different populations. With the aim of delivery and evaluation of 
interventions, new research will need to identify the key triggers and levers, which facilitate 
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the decision-making processes related to AAS use and progression to AAS use problems and 
potential dependence. These findings will be essential to inform the development and 
delivery of culturally sensitive interventions that address both personal and environmental 
factors. As the academic, multidisciplinary field of AAS use matures, we need to build on the 
low level, anecdotal and descriptive accounts of service provision that support the potential 
for tailored service provision resulting in ongoing service engagement with the target 
population. Further work is required relating to the reluctance and mistrust of health 
services, including primary care, amongst sections of the AAS using communities. The 
diverse typologies of AAS using populations with variable risk profiles and health concerns 
highlight the need for multiple approaches to meaningful health engagement. Finally, while 
for some populations, AAS use is just one aspect of risk behaviour alongside combinations of 
unprotected sex with multiple partners, psychoactive drug use, previous psychoactive drug 
injection, undiagnosed BBV status, previous incarceration while for others moderate AAS 
use may be a single factor within an otherwise health conscious lifestyle.  
 
Perhaps the main contribution of this thesis to the AAS evidence base, is the identification 
that the issues are far more complex and the population far more diverse than previously 
reported or recognised. While evidence based practice in relation to the prevention of AAS 
use and the reduction of harm amongst those that choose to use these drugs, remain 
distant goals, the research within the thesis provides a worthwhile contribution to the 
foundations on which to build.  
60 
 
Section 8: References 
 
ABBATE, V., KICMAN, A. T., EVANS-BROWN, M., MCVEIGH, J., COWAN, D. A., WILSON, C., 
COLES, S. J. & WALKER, C. J. 2015. Anabolic steroids detected in bodybuilding dietary 
supplements - a significant risk to public health. Drug Testing and Analysis, 7, 609-
618. 
ACMD 2010a. Annex for the ACMD Anabolic Steroids Report; A-F. 
ACMD 2010b. Consideration of the Anabolic Steroids. In: OFFICE, T. S. (ed.). London (UK). 
AGUILERA, R., CATLIN, D.H., BECCHI, M., PHILLIPS, A., WANG, C., SWERDLOFF, R.S., POPE, 
H.G. AND HATTON, C.K. 1999. Screening urine for exogenous testosterone by isotope 
ratio mass spectrometric analysis of one pregnanediol and two androstanediols. 
Journal of Chromatography B, 727, 95-105. 
AITKEN, C., DELALANDE, C. & STANTON, K. 2002. Pumping iron, risking infection? Exposure 
to hepatitis C, hepatitis B and HIV among anabolic–androgenic steroid injectors in 
Victoria, Australia. Drug and Alcohol Dependence, 65, 303-308. 
ANNITTO, W. J. & LAYMAN, W. A. 1980. Anabolic steroids and acute schizophrenic episode. J 
Clin Psychiatry, 41, 143-4. 
BACKHOUSE, S., COLLINS, C., DEFOORT, Y., MCNAMEE, M., PARKINSON, A. & SAUER, M. 
2014. Study on Doping Prevention: A map of Legal, Regulatory and Prevention 
Practice Provisions in EU 28. Luxembourg: Publications Office of the European Union. 
BACKHOUSE, S. H., GRIFFITHS, C. & MCKENNA, J. 2017. Tackling doping in sport: a call to 
take action on the dopogenic environment. Br J Sports Med. 
BACKHOUSE, S. H., WHITAKER, L. & PETROCZI, A. 2013. Gateway to doping? Supplement use 
in the context of preferred competitive situations, doping attitude, beliefs, and 
norms. Scand J Med Sci Sports, 23, 244-52. 
BAGGISH, A. L., WEINER, R. B., KANAYAMA, G., HUDSON, J. I., LU, M. T., HOFFMANN, U. & 
POPE, H. G., JR. 2017. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid 
Use. Circulation, 135, 1991-2002. 
BAGGISH, A. L., WEINER, R. B., KANAYAMA, G., HUDSON, J. I., PICARD, M. H., HUTTER, A. M. 
& POPE, H. G. 2010. Long-Term Anabolic-Androgenic Steroid Use Is Associated With 
Left Ventricular Dysfunction. Circulation-Heart Failure, 3, 472-U15. 
BAHRI, A., MAHFOUZ, M. S., MARRAN, N. M., DIGHRIRI, Y. H., ALESSA, H. S., KHWAJI, M. O. 
& ZAFAR, S. M. 2017. Prevalence and awareness of anabolic androgenic steroid use 
among male body builders in Jazan, Saudi Arabia. Tropical Journal of Pharmaceutical 
Research, 16, 1425-1430. 
BAHRKE, M. S., WRIGHT, J. E., O'CONNOR, J. S., STRAUSS, R. H. & CATLIN, D. H. 1990a. 
Selected psychological characteristics of anabolic-androgenic steroid users. N Engl J 
Med, 323, 834-5. 
BAHRKE, M. S., WRIGHT, J. E., STRAUSS, R. H. & CATLIN, D. H. 1992. Psychological moods 
and subjectively perceived behavioral and somatic changes accompanying anabolic-
androgenic steroid use. Am J Sports Med, 20, 717-24. 
BAHRKE, M. S. & YESALIS, C. E. 2002. Performance-Enhancing Substances in Sport and 
Exercise, Champaign, IL, Human Kinetics. 
BAHRKE, M. S. & YESALIS, C. E. 2004. Abuse of anabolic androgenic steroids and related 
substances in sport and exercise. Current Opinion in Pharmacology, 4, 614-620. 
61 
 
BAHRKE, M. S. & YESALIS, C. E., 3RD 1994. Weight training. A potential confounding factor in 
examining the psychological and behavioural effects of anabolic-androgenic steroids. 
Sports Med, 18, 309-18. 
BAHRKE, M. S., YESALIS, C. E., 3RD & WRIGHT, J. E. 1990b. Psychological and behavioural 
effects of endogenous testosterone levels and anabolic-androgenic steroids among 
males. A review. Sports Med, 10, 303-37. 
BAHRKE, M. S., YESALIS, C. E., 3RD & WRIGHT, J. E. 1996. Psychological and behavioural 
effects of endogenous testosterone and anabolic-androgenic steroids. An update. 
Sports Med, 22, 367-90. 
BAHRKE, M. S., YESALIS, C. E. & BROWER, K. J. 1998. Anabolic-androgenic steroid abuse and 
performance-enhancing drugs among adolescents. Child Adolesc Psychiatr Clin N Am, 
7, 821-38. 
BARRATT, M. J., FERRIS, J. A. & WINSTOCK, A. R. 2014. Use of Silk Road, the online drug 
marketplace, in the United Kingdom, Australia and the United States. Addiction, 109, 
774-83. 
BATES, G., BEGLEY, E., TOD, D., JONES, L., LEAVEY, C. & MCVEIGH, J. 2017a. A systematic 
review investigating the behaviour change strategies in interventions to prevent 
misuse of anabolic steroids. J Health Psychol, 1359105317737607. 
BATES, G., HOPE, V. & MCVEIGH, J. 2017b. HIV among people using anabolic steroids in the 
United Kingdom: an overview. HIV Nursing: Sharing best practice in HIV care. 
London: Medlscript Ltd. 
BATES, G., JONES, L. & MCVEIGH, J. 2013. Update of NICE Guidance PH18 on ‘Needle and 
syringe programmes’. PIEDs Review. Centre for Public Health: Liverpool John Moores 
University. 
BATES, G. & MCVEIGH, J. 2016. Image and Performance Enhancing Drugs 2015 Survey 
Results. Centre for Public Health: Liverpool John Moores University. 
BATES, G., TOD, D., LEAVEY, C. & MCVEIGH, J. 2018. An evidence-based socioecological 
framework to understand men’s use of anabolic androgenic steroids and inform 
interventions in this area. Drugs: Education, Prevention and Policy, 1-9. 
BATES, G., VAN HOUT, M. C., HEARNE, E., MACKRIDGE, A. & MCVEIGH, J. 2015. Evaluation of 
the pilot stage of the Pharmacy Needle Exchange Programme in Ireland. Liverpool: 
Liverpool John Moores University. 
BEGLEY, E., MCVEIGH, J., HOPE, V., BATES, G., GLASS, R., CAMPBELL, J., TANNER, C., KEAN, J., 
MORGAN, G., ACREMAN, D. & SMITH, J. 2017. Image and Performance Enhancing 
Drugs: 2016 National Survey Results. Liverpool: Liverpool John Moores University. 
BEST, D. & MIDGLEY, S. 1998. Assessing HIV risk behaviour among users of anabolic steroids 
in Newcastle-upon-tyne. The Journal of Performance Enhancing Drugs, 2, 20-23. 
BHASIN, S., STORER, T. W., BERMAN, N., CALLEGARI, C., CLEVENGER, B., PHILLIPS, J., 
BUNNELL, T. J., TRICKER, R., SHIRAZI, A. & CASABURI, R. 1996. The effects of 
supraphysiologic doses of testosterone on muscle size and strength in normal men. 
New England Journal of Medicine, 335, 1-7. 
BHASIN, S., WOODHOUSE, L., CASABURI, R., SINGH, A. B., BHASIN, D., BERMAN, N., CHEN, X. 
H., YARASHESKI, K. E., MAGLIANO, L., DZEKOV, C., DZEKOV, J., BROSS, R., PHILLIPS, J., 
SINHA-HIKIM, I., SHEN, R. Q. & STORER, T. W. 2001. Testosterone dose-response 
relationships in healthy young men. American Journal of Physiology-Endocrinology 
and Metabolism, 281, E1172-E1181. 
62 
 
BIRTLES, R. 1998. Trends in anabolic steroid use reported by agency based syringe exchange 
schemes 1992-1996. The Journal of Peformance Enhancing Drugs, 2, 22-29. 
BJORNEBEKK, A., WALHOVD, K. B., JORSTAD, M. L., DUE-TONNESSEN, P., HULLSTEIN, I. R. & 
FJELL, A. M. 2017. Structural Brain Imaging of Long-Term Anabolic-Androgenic 
Steroid Users and Nonusing Weightlifters. Biol Psychiatry, 82, 294-302. 
BMA 1909. Secret remedies: what they cost and what they contain, British Medical 
Association. 
BOARDLEY, I. D., GRIX, J. & DEWAR, A. J. 2014. Moral disengagement and associated 
processes in performance-enhancing drug use: a national qualitative investigation. 
Journal of Sports Sciences, 32, 836-844. 
BOLDING, G., SHERR, L. & ELFORD, J. 2002. Use of anabolic steroids and associated health 
risks among gay men attending London gyms. Addiction, 97, 195-203. 
BONATI, M. 2009. Once again, children are the main victims of fake drugs. Arch Dis Child, 94, 
468. 
BREINDAHL, T., EVANS-BROWN, M., HINDERSSON, P., MCVEIGH, J., BELLIS, M., STENSBALLE, 
A. & KIMERGARD, A. 2015. Identification and characterization by LC-UV-MS/MS of 
melanotan II skin-tanning products sold illegally on the Internet. DRUG TESTING AND 
ANALYSIS, 7, 164-172. 
BRENNAN, B. P., KANAYAMA, G., HUDSON, J. I. & POPE, H. G., JR. 2011. Human growth 
hormone abuse in male weightlifters. Am J Addict, 20, 9-13. 
BRENNAN, R., WELLS, J. S. & VAN HOUT, M. C. 2016. The injecting use of image and 
performance-enhancing drugs (IPED) in the general population: a systematic review. 
Health Soc Care Community. 
BRISTOW, C. 1988. Central 822 - the remarkable life of one of Britain's first women 
detectives, London, Transworld Publishers. 
BROADFIELD, D. 2017. Drug Misuse: Findings from the 2016/17 Crime Survey for England 
and Wales. Home Office. 
BROWER, K. J. 2002. Anabolic steroid abuse and dependence. Current psychiatry reports, 4, 
377-387. 
BROWER, K. J., BLOW, F. C., BERESFORD, T. P. & FUELLING, C. 1989. Anabolic-androgenic 
steroid dependence. J Clin Psychiatry, 50, 31-3. 
BROWER, K. J., BLOW, F. C., YOUNG, J. P. & HILL, E. M. 1991a. Symptoms and correlates of 
anabolic-androgenic steroid dependence. Br J Addict, 86, 759-68. 
BROWER, K. J., CATLIN, D. H., BLOW, F. C., ELIOPULOS, G. A. & BERESFORD, T. P. 1991b. 
Clinical assessment and urine testing for anabolic-androgenic steroid abuse and 
dependence. Am J Drug Alcohol Abuse, 17, 161-71. 
BROWER, K. J., ELIOPULOS, G. A., BLOW, F. C., CATLIN, D. H. & BERESFORD, T. P. 1990. 
Evidence for physical and psychological dependence on anabolic androgenic steroids 
in eight weight lifters. Am J Psychiatry, 147, 510-2. 
BRUNEEL, C. A., BEN LAKHDAR, C. & VAILLANT, N. G. 2014. Are "Legal Highs" Users Satisfied? 
Evidence from Online Customer Comments. Substance Use & Misuse, 49, 364-373. 
BRYDEN, A. A., ROTHWELL, P. J. & O'REILLY, P. H. 1995. Anabolic steroid abuse and renal-cell 
carcinoma. Lancet, 346, 1306-7. 
BUCKLEY, W. E. 1988. Estimated Prevalence of Anabolic Steroid Use Among Male High 
School Seniors. JAMA, 260, 3441. 
BURTON, C. 1996. Anabolic steroid use among the gym population in Clwyd. The 
Pharmaceutical Journal, 256, 557-560. 
63 
 
CABASSO, A. 1994. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc, 26, 2-
4. 
CAFRI, G., THOMPSON, J. K., RICCIARDELLI, L., MCCABE, M., SMOLAK, L. & YESALIS, C. 2005. 
Pursuit of the muscular ideal: Physical and psychological consequences and putative 
risk factors. Clin Psychol Rev, 25, 215-39. 
CAFRI, G., VAN DEN BERG, P. & THOMPSON, J. K. 2006. Pursuit of Muscularity in Adolescent 
Boys: Relations Among Biopsychosocial Variables and Clinical Outcomes. Journal of 
Clinical Child & Adolescent Psychology, 35, 283-291. 
CHANDLER, M. & MCVEIGH, J. 2014. Steroids and image enhancing drugs 2013 survey 
results. Liverpool: LJMU Centre for Public Health. 
CHANDLER, M., MCVEIGH, J. & BEYNON, C. 2009. Integrating drug related monitoring 
systems - An intelligence led approach. 
CHANDLER, M., MCVEIGH, J. AND BEYNON, C. 2009. Integrating drug-related monitoring 
systems - An intelligence led approach. Contemporary Drug Problems, 36, 663-84. 
CHANDLER, M. A. M., J. 2013. Steroids and Image Enhancing Drugs; 2013 Survey Results. 
Center for Public Health: Liverpool John Moores University. 
CHINERY, S. 1993. Anabolic steroids and bodybuilding, New Jersey, SMS Publishing. 
CHOI, P. Y. & POPE, H. G., JR. 1994. Violence toward women and illicit androgenic-anabolic 
steroid use. Ann Clin Psychiatry, 6, 21-5. 
CHRISTIANSEN, A. V., VINTHER, A. S. & LIOKAFTOS, D. 2016. Outline of a typology of men’s 
use of anabolic androgenic steroids in fitness and strength training environments. 
Drugs. 
COHEN, J., COLLINS, R., DARKES, J. & GWARTNEY, D. 2007. A league of their own: 
demographics, motivations and patterns of use of 1,955 male adult non-medical 
anabolic steroid users in the United States. Journal of the International Society of 
Sports Nutrition, 4. 
COLE, C., JONES, L., MCVEIGH, J., KICMAN, A., SYED, Q. & BELLIS, M. 2011. Adulterants in 
illicit drugs: a review of empirical evidence. Drug Test Anal, 3, 89-96. 
COOK, P. A., MCVEIGH, J., PATEL, A., SYED, Q. & MUTTON, K. 2000. Hepatitis C in injecting 
drug users in the North West. Liverpool: Liverpool John Moores University. 
COOMBER, R., PAVLIDIS, A., SANTOS, G. H., WILDE, M., SCHMIDT, W. & REDSHAW, C. 2014. 
The supply of steroids and other performance and image enhancing drugs (PIEDs) in 
one English city: Fakes, counterfeits, supplier trust, common beliefs and access. 
Performance Enhancement & Health, 3, 135-144. 
CORAZZA, O., BERSANI, F. S., BRUNORO, R., VALERIANI, G., MARTINOTTI, G. & SCHIFANO, F. 
2014. The diffusion of Performance and Image-Enhancing Drugs (PIEDs) on the 
Internet: The Abuse of the Cognitive Enhancer Piracetam. Substance Use & Misuse, 
49, 1849-1856. 
CORAZZA, O., PARROTT, A. C. & DEMETROVICS, Z. 2017. Novel psychoactive substances: 
Shedding new lights on the ever-changing drug scenario and the associated health 
risks. Human Psychopharmacology-Clinical and Experimental, 32. 
CORDARO, F. G., LOMBARDO, S. & COSENTINO, M. 2011. Selling androgenic anabolic 
steroids by the pound: identification and analysis of popular websites on the 
Internet. Scand J Med Sci Sports, 21, e247-59. 
CRAMPIN, A. C., LAMAGNI, T. L., HOPE, V. D., NEWHAM, J. A., LEWIS, K. M., PARRY, J. V. & 
GILL, O. N. 1998. The risk of infection with HIV and hepatitis B in individuals who 
inject steroids in England and Wales. Epidemiology and Infection, 121, 381-386. 
64 
 
CREAGH, T. M., RUBIN, A. & EVANS, D. J. 1988. Hepatic tumours induced by anabolic 
steroids in an athlete. J Clin Pathol, 41, 441-3. 
CSAKY, T. Z. 1972. Doping. J Sports Med Phys Fitness, 12, 117-23. 
CURTIN, M., DILLON, L., GALVIN, B., GUINEY, C., LYONS, S. & MILLAR, S. 2017. Focal Point 
Ireland: national report for 2016– Drugs Ireland. Dublin: Health Research Board. 
DARCY, C. 2016. Ireland’s steroid boom among young gym goers. The Irish Times, 4/6/2017. 
DAWSON, R. T. 2001. Drugs in sport - the role of the physician. Journal of Endocinology, 170, 
55-61. 
DAWSON, R. T. & HARRISON, M. W. 1996. Thyroxine Induced Muscle Damage in a 
Bodybuilder. Journal of Performance Enhancing Drugs, 1, 144-145. 
DAY, C. A., TOPP, L., IVERSEN, J., MAHER, L. & COLLABORATION OF AUSTRALIAN, N. 2008. 
Blood-borne virus prevalence and risk among steroid injectors: results from the 
Australian Needle and Syringe Program Survey. Drug Alcohol Rev, 27, 559-61. 
DE KRUIF, P. 1945. The Male Hormone, London: Harcourt, Brace and Company. 
DE TARDE, G. 1903. The laws of imitation, New York, H. Holt and Co. 
DELALANDE, C. L., AITKEN, C. K., MERCURI, P. & STANTON, K. A. 1998. Risky practices among 
people who inject steroids. Med J Aust, 169, 62. 
DENHAM, B. E. 2006. The Anabolic Steroid Control Act of 2004: a study in the political 
economy of drug policy. J Health Soc Policy, 22, 51-78. 
DEPARTMENT OF HEALTH 2017. Drug misuse and dependence: UK guidelines on clinical 
management. London: Department of Health. 
DICKERMAN, R. D., SCHALLER, F., PRATHER, I. & MCCONATHY, W. J. 1995. Sudden cardiac 
death in a 20-year-old bodybuilder using anabolic steroids. Cardiology, 86, 172-3. 
DICKINSON, B. P. & RICH, J. D. 1996. Infections Secondary to Anabolic Steroid Misuse and 
Their Prevention. Journal of  Perfomance Enhancing Drugs, 1, 146-150. 
DICLEMENTE, R. 2014. Steroid Use, Health Risk Behaviors and Adverse Health Indicators 
among U.S. High School Students. Family Medicine & Medical Science Research, 03. 
DIMEO, P. 2007. A history of drug use in sport 1876 - 1976: beyond good and evil, Abingdon, 
UK, Routledge. 
DRISCOLL, M. D., ARORA, A. & BRENNAN, M. L. 2011. Intramuscular anabolic steroid 
injection leading to life-threatening clostridial myonecrosis: a case report. J Bone 
Joint Surg Am, 93, e92 1-3. 
DUBIN, D. 1990. Commission of inquiry into the use of drugs and banned practices intended 
to increase athletic performance. Ottawa: Canadian Government Publishing Center. 
DUCHAINE, D. 1989. Underground steroid handbook II. Venice (CA): HLR Technical Books. 
DURANT, R. H., ESCOBEDO, L. G. & HEATH, G. W. 1995. Anabolic-Steroid Use, Strength 
Training, and Multiple-Drug Use among Adolescents in the United-States. Pediatrics, 
96, 23-28. 
DURANT, R. H., RICKERT, V. I., ASHWORTH, C. S., NEWMAN, C. & SLAVENS, G. 1993. Use of 
Multiple Drugs among Adolescents Who Use Anabolic Steroids. New England Journal 
of Medicine, 328, 922-926. 
EATON, G., MORLEO, M., LODWICK, A., BELLIS, M. & MCVEIGH, J. 2006. United Kingdom 
drug situation: annual report to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) 2005. London: Department of Health. 
ESPOSITO, S., DEVENTER, K. & VAN EENOO, P. 2012. Characterization and identification of a 
C-terminal amidated mechano growth factor (MGF) analogue in black market 
products. Rapid Commun Mass Spectrom, 26, 686-92. 
65 
 
EVANS-BROWN, M., DAWSON, R., CHANDLER, M. & MCVEIGH, J. 2009a. Use of melanotan I 
and II in the general population. British Medical Journal, 338. 
EVANS-BROWN, M., KIMERGARD, A. & MCVEIGH, J. 2009b. Elephant in the room? The 
methodological implications for public health research of performance-enhancing 
drugs derived from the illicit market. DRUG TESTING AND ANALYSIS, 1, 323-326. 
EVANS-BROWN, M., KIMERGARD, A., MCVEIGH, J., CHANDLER, M. & BRANDT, S. D. 2014. 
BODYBUILDING SUPPLEMENTS Is the breast cancer drug tamoxifen being sold as a 
bodybuilding dietary supplement? Bmj-British Medical Journal, 348. 
EVANS-BROWN, M. & MCVEIGH, J. 2008. An Introduction to Anabolic Steroids. SportEX 
Medicine, 38, 20-26. 
EVANS-BROWN, M. & MCVEIGH, J. 2009a. Anabolic Steroid use in the general population of 
the United Kingdom. In: MOLLER, V., MCNAMEE, M. AND DIMEO, P. (ed.) Elite Sport, 
Doping and Public Health. Denmark: University Press of Southern Denmark and The 
Danish Ministry of Culture. 
EVANS-BROWN, M. & MCVEIGH, J. 2009b. Injecting human growth hormone as a 
performance-enhancing drug-perspectives from the United Kingdom. JOURNAL OF 
SUBSTANCE USE, 14, 267-288. 
EVANS-BROWN, M., MCVEIGH, J., PERKINS, C. & BELLIS, M. 2012. Human enhancement 
drugs: the emerging challenges to public health. Liverpool: North West Public Health 
Observatory. 
EVANS, N. A. 2004. Current Concepts in Anabolic-Androgenic Steroids. American Journal of 
Sports Medicine, 32, 534-542. 
FAIR, J. D. 1993. Isometrics or Steroids - Exploring New Frontiers of Strength in the Early 
1960s. Journal of Sport History, 20, 1-24. 
FERENCHICK, G. S. & ADELMAN, S. 1992. Myocardial infarction associated with anabolic 
steroid use in a previously healthy 37-year-old weight lifter. Am Heart J, 124, 507-8. 
FERNANDEZ, F. M., HOSTETLER, D., POWELL, K., KAUR, H., GREEN, M. D., MILDENHALL, D. C. 
& NEWTON, P. N. 2011. Poor quality drugs: grand challenges in high throughput 
detection, countrywide sampling, and forensics in developing countries. Analyst, 
136, 3073-82. 
FRANCIS, C. 1990. Speed Trap, London, Collins. 
FRANKLE, M. A., EICHBERG, R. & ZACHARIAH, S. B. 1988. Anabolic androgenic steroids and a 
stroke in an athlete: case report. Arch Phys Med Rehabil, 69, 632-3. 
FRIEDLE, K. E. 1993. Effects of anabolic steroids on physical health Anabolic steroids in sport 
and exercise. Human Kinetics Publishers. 
GALLAWAY, S. 1997. The steroid bible, Honolulu, Belle International. 
GARNER, S. T. & MILES, N. A. 1985. Abuse of Anabolic-Steroids. British Medical Journal, 291, 
741-741. 
GDS. 2015. Global Drug Survey [Online]. Available: www.globaldrugsurvey.com [Accessed 
25/04/2016 2016]. 
GERMAIN, J., HARRIS, J., MACKAY, S. & MAXWELL, C. 2017. Why Should We Use Online 
Research Methods? Four Doctoral Health Student Perspectives. Qual Health Res, 
1049732317721698. 
GERRITSMA, E. J., BROCAAR, M. P., HAKKESTEEGT, M. M. & BIRKENHAGER, J. C. 1994. 
Virilization of the Voice in Postmenopausal Women Due to the Anabolic-Steroid 
Nandrolone Decanoate (Decadurabolin) - the Effects of Medication for One-Year. 
Clinical Otolaryngology, 19, 79-84. 
66 
 
GLASS, R., HOPE, V. D., NJOROGE, J., EDMUNDSON, C., SMITH, J., MCVEIGH, J., PARRY, J. & 
DESAI, M. 2018. Secondary distribution of injecting equipment obtained from needle 
and syringe programmes by people injecting image and performance enhancing 
drugs: England and Wales, 2012-15. Drug Alcohol Depend, 195, 40-44. 
GOLDMAN, B. 1984. Death in the locker room, Chicago, Elite Sports Medicines Publications. 
GOLUB, A., JOHNSON, B. D. & DUNLAP, E. 2005. Subcultural evolution and illicit drug use. 
Addiction Research & Theory, 13, 217-229. 
GRAHAM, M. R., RYAN, P., BAKER, J. S., DAVIES, B., THOMAS, N.-E., COOPER, S.-M., EVANS, 
P., EASMON, S., WALKER, C. J. & COWAN, D. 2009. Counterfeiting in performance-
and image-enhancing drugs. Drug testing and analysis, 1, 135. 
GREEN, M. P., HARVEY, A. J., SPATE, L. D., KIMURA, K., THOMPSON, J. G. & ROBERTS, R. M. 
2016. The effects of 2,4-dinitrophenol and d-glucose concentration on the 
development, sex ratio, and interferon-tau (IFNT) production of bovine blastocysts. 
Mol Reprod Dev, 83, 50-60. 
GRIFFITHS, S., HENSHAW, R., MCKAY, F. H. & DUNN, M. 2016. Post-cycle therapy for 
performance and image enhancing drug users: A qualitative investigation. 
Performance Enhancement & Health. 
GRIFFITHS, S., JACKA, B., DEGENHARDT, L., MURRAY, S. B. & LARANCE, B. 2018. Physical 
appearance concerns are uniquely associated with the severity of steroid 
dependence and depression in anabolic-androgenic steroid users. Drug Alcohol Rev. 
GROGAN, S., SHEPHERD, S., EVANS, R., WRIGHT, S. & HUNTER, G. 2006. Experiences of 
anabolic steroid use: in-depth interviews with men and women body builders. J 
Health Psychol, 11, 845-56. 
GRUBER, A. J. & POPE, H. G. 1999. Compulsive weight lifting and anabolic drug abuse among 
women rape victims. Compr Psychiatry, 40. 
GRUNDING, P. & BACHMANN, M. 1995. World Anabolic Review 1996, M.B. Muscle Books. 
GRUNDLINGH, J., DARGAN, P. I., EL-ZANFALY, M. & WOOD, D. M. 2011. 2,4-dinitrophenol 
(DNP): a weight loss agent with significant acute toxicity and risk of death. J Med 
Toxicol, 7, 205-12. 
HAKANSSON, A., MICKELSSON, K., WALLIN, C. & BERGLUND, M. 2012. Anabolic Androgenic 
Steroids in the General Population: User Characteristics and Associations with 
Substance Use. European Addiction Research, 18, 83-90. 
HART, M. 1993. Steroids: the layman's guide, United Kingdom, Mick Hart Training Systems. 
HEFFERNAN, T., BATTERSBY, L., BISHOP, T. & O'NEILL, T. 2015. The Everyday Cognitive 
Consequences of Regular Use of Anabolic Androgenic Steroids in a Sporting Context. 
European Psychiatry, 30. 
HENRION, R., MANDELBROT, L. & DELFIEU, D. 1992. Contamination par le VIH a la suite 
d'injections d'anabolisants. La presse medicale, 21. 
HM GOVERNMENT 2017. 2017 Drug Strategy. London. 
HOBERMAN, J. M. 2001. Testosterone dreams, Berkeley, Ca, University of California Press. 
HOBERMAN, J. M. & YESALIS, C. E. 1995. The history of synthetic testosterone. Sci Am, 272, 
76-81. 
HOPE, V., MCVEIGH, J., MARONGIU, A., EVANS-BROWN, M., SMITH, J., KIMERGARD, A., 
CROXFORD, S., BEYNON, C., PARRY, J., BELLIS, P. M. & NCUBE, F. 2013a. Prevalence 
of, and risk factors for, human immunodeficiency virus, hepatitis B and hepatitis C 
infections among men who inject image- and performance-enhancing drugs in 
England & Wales. HIV MEDICINE, 14, 2-2. 
67 
 
HOPE, V., MCVEIGH, J., SMITH, J., GLASS, R., NJOROGE, J., TANNER, C., PARRY, J. V., NCUBE, 
F. & DESAI, M. 2017. Low levels of hepatitis C diagnosis and testing uptake among 
people who inject image and performance enhancing drugs in England and Wales, 
2012-15. Drug and Alcohol Dependence, 179, 83-86. 
HOPE, V. D., HARRIS, R., MCVEIGH, J., CULLEN, K. J., SMITH, J., PARRY, J. V., DEANGELIS, D. & 
NCUBE, F. 2016. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject 
Image and Performance Enhancing Drugs in England and Wales: Results From Cross-
Sectional Prevalence Surveys, 1992-2013. Jaids-Journal of Acquired Immune 
Deficiency Syndromes, 71, 331-337. 
HOPE, V. D., MARONGIU, A., PARRY, J. V. & NCUBE, F. 2010. The extent of injection site 
infection in injecting drug users: findings from a national surveillance study. 
Epidemiol Infect, 138, 1510-8. 
HOPE, V. D., MCVEIGH, J., MARONGIU, A., EVANS-BROWN, M., SMITH, J., KIMERGARD, A., 
CROXFORD, S., BEYNON, C. M., PARRY, J. V. & BELLIS, M. A. 2013b. Prevalence of, 
and risk factors for, HIV, hepatitis B and C infections among men who inject image 
and performance enhancing drugs: a cross-sectional study. BMJ OPEN, 3. 
HOPE, V. D., MCVEIGH, J., MARONGIU, A., EVANS-BROWN, M., SMITH, J., KIMERGARD, A., 
CROXFORD, S., BEYNON, C. M., PARRY, J. V., BELLIS, M. A. & NCUBE, F. 2013c. 
Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who 
inject image and performance enhancing drugs: a cross-sectional study. BMJ Open, 
3, e003207-e003207. 
HOPE, V. D., MCVEIGH, J., MARONGIU, A., EVANS-BROWN, M., SMITH, J., KIMERGARD, A., 
PARRY, J. V. & NCUBE, F. 2015. Injection site infections and injuries in men who inject 
image- and performance-enhancing drugs: prevalence, risks factors, and healthcare 
seeking. EPIDEMIOLOGY AND INFECTION, 143, 132-140. 
HOXHA, B. & PETROCZI, A. 2015. Playing with fire? Factors influencing risk willingness with 
the unlicensed fat burner drug 2,4-Dinitrophenol (DNP) in young adults. Public 
Health, 129, 1519-22. 
HPA, HEALTH PROTECTION AGENCY, HEALTH PROTECTION SCOTLAND, PUBLIC HEALTH 
WALES & IRELAND., P. H. A. N. 2012. Shooting Up: infections among people who 
inject drugs in the UK 2011. . London: Health Protection Agency. 
HUIE, M. J. 1994. An acute myocardial infarction occurring in an anabolic steroid user. Med 
Sci Sports Exerc, 26, 408-13. 
IP, E. J., BARNETT, M. J., TENEROWICZ, M. J., KIM, J. A., WEI, H. & PERRY, P. J. 2010. Women 
and anabolic steroids: an analysis of a dozen users. Clin J Sport Med, 20, 475-81. 
IP, E. J., YADAO, M. A., SHAH, B. M., DOROUDGAR, S., PERRY, P. J., TENEROWICZ, M. J., 
NEWSOM, L., MANN, A. A., MKRTCHYAN, H. & POPE, H. G. 2017. Polypharmacy, 
Infectious Diseases, Sexual Behavior, and Psychophysical Health Among Anabolic 
Steroid-Using Homosexual and Heterosexual Gym Patrons in San Francisco's Castro 
District. Substance Use & Misuse, 52, 959-968. 
IVERSEN, J., HOPE, V. D. & MCVEIGH, J. 2016. Access to needle and syringe programs by 
people who inject image and performance enhancing drugs. International Journal of 
Drug Policy, 31, 199-200. 
IVERSEN, J., TOPP, L., WAND, H. & MAHER, L. 2013. Are people who inject performance and 
image-enhancing drugs an increasing population of Needle and Syringe Program 
attendees? Drug and Alcohol Review, 32, 205-207. 
68 
 
JENNINGS, C. J., PATTEN, E., KENNEDY, M. C. & KELLY, C. 2014. Examining the profile and 
perspectives of individuals attending harm reduction services who are users of 
performance and image enhancing drugs. Dublin: Merchants Quay Ireland. 
JOHNSON, M. D., JAY, M. S., SHOUP, B. & RICKERT, V. I. 1989. Anabolic-Steroid Use by Male-
Adolescents. Pediatrics, 83, 921-924. 
JONES, F. 2017. Fianna Fáil: Rise of illegal anabolic steroid use "worrying" [Online]. Dublin: 
Newstalk 106-108fm. Available: http://www.newstalk.com/Fianna-Fil:-Rise-of-illegal-
anabolic-steroid-use-worrying [Accessed 2018]. 
JONES, L., BATES, G., BELLIS, M., BEYNON, C., DUFFY, P., EVANS-BROWN, M., MACKRIDGE, 
A., MCCOY, E., SUMNALL, H. & MCVEIGH, J. 2011. A summary of the health harms of 
drugs. London: The Department of Health. 
JONES, L., BATES, G. AND MCVEIGH, J. 2013. Update of NICE Guidance PH18 on ‘Needle and 
syringe programmes’. Qualitative and quantitative review updates 2013. Centre for 
Public Health: Liverpool John Moores University. 
JONES, L., PICKERING, L., SUMNALL, H., MCVEIGH, J. & BELLIS, M. 2008. A review of the 
effectiveness and cost-effectivess of needle and syringe programmes for injecting 
drug users. Centre for Public Health: Liverpool John Moores University. 
JONES, L., PICKERING, L., SUMNALL, H., MCVEIGH, J. & BELLIS, M. 2010. Optimal provision of 
needle and syringe programmes for injecting drug users: A systematic review. 
International Journal of Drug Policy, 21, 335-342. 
JUENGST, E. T. 2000. What does enhancement mean? In: E, P. (ed.) Enhancing human traits: 
ethical and social implications. Washington: Georgetown University Press. 
KANAYAMA, G., BROWER, K. J., WOOD, R. I., HUDSON, J. I. & POPE, H. G. 2010a. Treatment 
of anabolic-androgenic steroid dependence: Emerging evidence and its implications. 
Drug and Alcohol Dependence, 109, 6-13. 
KANAYAMA, G., HUDSON, J. I., DELUCA, J., ISAACS, S., BAGGISH, A., WEINER, R., BHASIN, S. 
& POPE, H. G. 2015. Prolonged hypogonadism in males following withdrawal from 
anabolic-androgenic steroids: an under-recognized problem. Addiction, 110, 823-
831. 
KANAYAMA, G., HUDSON, J. I. & POPE, H. G. 2010b. Illicit anabolic–androgenic steroid use. 
Hormones and Behavior, 58, 111-121. 
KANAYAMA, G., KEAN, J., HUDSON, J. I. & POPE, H. G., JR. 2013. Cognitive deficits in long-
term anabolic-androgenic steroid users. Drug Alcohol Depend, 130, 208-14. 
KANAYAMA, G., POPE, H. G. & HUDSON, J. I. 2018. Associations of anabolic-androgenic 
steroid use with other behavioral disorders: an analysis using directed acyclic graphs. 
Psychological medicine, 1-8. 
KATZ, E., LAZARSFELD, P. & ROPER, E. 2017. Personal Influence, the Part Played by People in 
the Flow of Mass Communications New York, Routledge. 
KAUFMAN, M. J., JANES, A. C., HUDSON, J. I., BRENNAN, B. P., KANAYAMA, G., KERRIGAN, A. 
R., JENSEN, J. E. & POPE, H. G., JR. 2015. Brain and cognition abnormalities in long-
term anabolic-androgenic steroid users. Drug Alcohol Depend, 152, 47-56. 
KEAN, J. A. M., J. 2014. NICE of you to notice. Image and Preformance -Enhancing Drugs 
(IPED). Druglink. 
KENNEDY, M. C. 1992. Anabolic steroid abuse and toxicology. Aust N Z J Med, 22, 374-81. 
KENNEDY, M. C. & LAWRENCE, C. 1993. Anabolic steroid abuse and cardiac death. Med J 
Aust, 158, 346-8. 
69 
 
KICMAN, A. T. 2008a. Pharmacology of anabolic steroids. British Journal of Pharmacology, 
154, 502-521. 
KICMAN, A. T. 2008b. Pharmacology of anabolic steroids. Br J Pharmacol, 154, 502-21. 
KICMAN, A. T. 2010. Biochemical and physiological aspects of endogenous androgens. 
Handb Exp Pharmacol, 25-64. 
KICMAN, A. T. & GOWER, D. B. 2003. Anabolic steroids in sport: biochemical, clinical and 
analytical perspectives. Annals of Clinical Biochemistry, 40, 321-356. 
KICMAN, A. T., HOUGHTON, E. & GOWER, D. B. 2010. Anabolic Steroids: Metabolism, Doping 
and Detection in Human and Equestrian Sports. Steroid Analysis: Second Edition, 
743-836. 
KIMERGARD, A. 2015. A qualitative study of anabolic steroid use amongst gym users in the 
United Kingdom: motives, beliefs and experiences. Journal of Substance Use, 20, 
288-294. 
KIMERGARD, A., BREINDAHL, T., HINDERSSON, P. & MCVEIGH, J. 2014a. The composition of 
anabolic steroids from the illicit market is largely unknown: implications for clinical 
case reports. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 107, 597-598. 
KIMERGARD, A. & MCVEIGH, J. 2014a. Environments, risk and health harms: a qualitative 
investigation into the illicit use of anabolic steroids among people using harm 
reduction services in the UK. BMJ OPEN, 4. 
KIMERGARD, A. & MCVEIGH, J. 2014b. Variability and dilemmas in harm reduction for 
anabolic steroid users in the UK: a multi-area interview study. HARM REDUCTION 
JOURNAL, 11. 
KIMERGARD, A. & MCVEIGH, J. 2014c. Variability and dilemmas in harm reduction for 
anabolic steroid users in the UK: a multi-area interview study. Harm Reduction 
Journal, 11. 
KIMERGARD, A., MCVEIGH, J., KNUTSSON, S., BREINDAHL, T. & STENSBALLE, A. 2014b. 
Online marketing of synthetic peptide hormones: poor manufacturing, user safety, 
and challenges to public health. DRUG TESTING AND ANALYSIS, 6, 396-398. 
KLEINMAN, C. C. & PETIT, C. E. 1993. Legal aspects of anabolic steroid use and abuse. In: 
YESALIS, C. E. (ed.) Anabolic steroids in sport and exercise. Champaign, IL: Human 
Kinetics. 
KOCH, R. A., LEE, R. C. & TAINTER, M. L. 1935. Dinitrophenol on Liver Function. Cal West 
Med, 43, 337-9. 
KOCHAKIAN, C. D. 1975. Definition of androgens and protein anabolic steroids. Pharmacol 
Ther B, 1, 149-77. 
KOCHAKIAN, C. D. 1976. Anabolic-androgenic steroids, New York, Springer-Verlag. 
KOMOROSKI, E. M. 1992. Adolescent Body Image and Attitudes to Anabolic Steroid Use. 
Arch Pediatr Adolesc Med, 146, 823. 
KOPERA, H. 1993. Anabolic-Androgenic Steroids Towards the Year 2000, Blackwell-Mzv. 
KORKIA, P. 1998a. Adverse effects of anabolic-androgenic steroids a review. Journal of 
substance misuse, 3, 34-41. 
KORKIA, P. 1998b. Psychological effects of anabolic steroid use: a review. Journal of 
Substance Misuse, 3, 106-113. 
KORKIA, P. 2000. Drugs in sport. Journal of Substance Use, 4, 125-127. 
KORKIA, P., LENEHAN, P. & MCVEIGH, J. 1996. Non-medical use of androgens among 
women. The Journal of Preformance Enhancing Drugs, 1, 71. 
70 
 
KORKIA, P. & STIMSON, G. 1997. Indications of Prevalence, Practice and Effects of Anabolic 
Steroid Use in Great Britain. International Journal of Sports Medicine, 18, 557-562. 
KORKIA, P. & STIMSON, G. V. 1993. Anabolic Steroid Use in Great Britain: An Exploratory 
Investigation : Final Report to the Departments of Health for England, Scotland and 
Wales, London, Centre for Research on Drugs Health Behaviour  
KOZINETS, R. V. 2013. NETNOGRAPHY AND THE DIGITAL CONSUMER The quest for cultural 
insights. Routledge Companion to Digital Consumption, 93-101. 
KRUSKEMPER, H. 1968. Anabolic steroids: , New York, Academic Press. 
LARANCE, B., DEGENHARDT, L., COPELAND, J. & DILLON, P. 2008. Injecting risk behaviour 
and related harm among men who use performance- and image-enhancing drugs. 
Drug and Alcohol Review, 27, 679-686. 
LEIT, R. A., GRAY, J. J. & POPE, H. G. 2002. The media's representation of the ideal male 
body: A cause for muscle dysmorphia? Int. J. Eat. Disord., 31, 334-338. 
LENEHAN, P. 2003. Anabolic steroids and other performance enhancing drugs, London, 
Taylor and Francis. 
LENEHAN, P., BELLIS, M. & MCVEIGH, J. 1996. A study of anabolic steroid use in the North 
West of England. Journal of Performance Enhancing Drugs, 1. 
LENEHAN, P. & MCVEIGH, J. 1994. HIV and steroid use. Relay, 1, 19-20. 
LENEHAN, P. & MCVEIGH, J. 1998. Anabolic steroids: a guide for professionals., Liverpool, 
University of Liverpool. 
LLEWELLYN, W. 2011. Sport Supplement Reference Guide, Jupiter, Florida, Molecular 
Nutrition. 
LLEWELLYN, W. 2017. Anabolics. 11 ed. Jupiter, FL: Molecular Nutrition. 
LLEWELLYN, W. & TOBER, R. 2010. Underground Anabolics, Jupiter, FL, Body of Science. 
LOI, B., ZLOH, M., DE LUCA, M. A., PINTORI, N., CORKERY, J. & SCHIFANO, F. 2017. 4,4-
Dimethylaminorex ("4,4-DMAR"; "Serotoni") misuse: A Web-based study. Human 
Psychopharmacology-Clinical and Experimental, 32. 
LONGOBARDI, C., PRINO, L. E., FABRIS, M. A. & SETTANNI, M. 2017. Muscle dysmorphia and 
psychopathology: Findings from an Italian sample of male bodybuilders. Psychiatry 
Res, 256, 231-236. 
LUETKEMEIER, M. J., BAINBRIDGE, C. N., WALKER, J., BROWN, D. B. & EISENMAN, P. A. 1995. 
Anabolic-Androgenic Steroids: Prevalence, Knowledge, and Attitudes in Junior and 
Senior High School Students. Journal of Health Education, 26, 4-13. 
LUKE, J. L., FARB, A., VIRMANI, R. & SAMPLE, R. H. 1990. Sudden cardiac death during 
exercise in a weight lifter using anabolic androgenic steroids: pathological and 
toxicological findings. J Forensic Sci, 35, 1441-7. 
LYNGBERG, K. K. 1991. [Myocardial infarction and death of a body builder after using 
anabolic steroids]. Ugeskr Laeger, 153, 587-8. 
MACQUEEN, I. J. 1967. Body building on drugs. British Medical Journal, 4, 743-744. 
MALARKEY, W. B., STRAUSS, R. H., LEIZMAN, D. J., LIGGETT, M. & DEMERS, L. M. 1991. 
Endocrine effects in female weight lifters who self-administer testosterone and 
anabolic steroids. Am J Obstet Gynecol, 165. 
MCBRIDE, A. J., WILLIAMSON, K. & PETERSEN, T. 1996. Three cases of nalbuphine 
hydrochloride dependence associated with anabolic steroid use. British Journal of 
Sports Medicine, 30, 69-70. 
71 
 
MCELRATH, K. & CONNOLLY, D. 2006. Nalbuphine (Nubain): non-prescribed use, injecting, 
and risk behaviors for bloodborne viruses. Contemporary Drug Problems, 33, 321 - 
340. 
MCKILLOP, G. 1987. Drug abuse in body builders in the West of Scotland. Scottish medical 
journal, 32, 39-41. 
MCVEIGH, J. 1996. Survey of gym owners' opinions on the use of preformance enhancing 
drugs. The Journal of Preformance Enhancing Drugs, 1, 21. 
MCVEIGH, J. 2007. The injectors that harm reduction forgot. 18th International conference 
on the rudection of drug related harm. Warsaw, Poland. 
MCVEIGH, J. 2017a. Anabolic steroids: a global public health perspective. . Lisbon Addictions 
2nd European conference on addictive behaviour and dependencies. Lisbon. 
MCVEIGH, J. 2017b. Changes in IPED use and concerns over last 20 years. Institute for Health 
Research Image and Performance Enhancing Drug Use Conference  Liverpool. 
MCVEIGH, J. 2017c. Image and performance enhancing drug use in the United Kingdom: 
challenges and implications  
Doping in Sport, Doping in Society – Lessons, Themes and Connections Conference.  . Aarhus. 
MCVEIGH, J. 2017d. Nice guideline on drug misuse prevention (NG64) Expert testimony: The 
use of IPEDs in the UK. National Institute of Health and Care Excellence London: 
NICE. 
MCVEIGH, J. 2017e. The range of IPEDs, user populations and motivations for use. Scottish 
Drugs Forum – Image and Performance Enhancing Drugs Conference   
Glasgow. 
MCVEIGH, J. 2018a. Anabolic androgenic steroids & HIV: prevalence, risks & implications. 
Fourth Joint Conference of BHIVA with BASHH. Edinburgh 
 
MCVEIGH, J. 2018b. The public health implications of anabolic steroid use in the United 
Kingdom. A shot in the Dark: Steroids, IPEDs - the Hidden Harm Conference. 
Colchester. 
MCVEIGH, J., BATES, G. & CHANDLER, M. 2015a. Steroids and Image Enhancing Drugs. 
Centre for Public Health: Liverpool John Moores University. 
MCVEIGH, J., BATES, G. & CHANDLER, M. 2015b. Steroids and Image Enhancing Drugs 2014 
Survey Results. Centre for Public Health, Liverpool John Moores University. 
MCVEIGH, J. & BEGLEY, E. 2017. Anabolic steroids in the UK: an increasing issue for public 
health. Drugs: Education, Prevention and Policy, 24, 278-285. 
MCVEIGH, J., BEYNON, C. & BELLIS, M. A. 2003a. New challenges for agency based syringe 
exchange schemes: analysis of 11 years of data (1991–2001) in Merseyside and 
Cheshire, United Kingdom. International Journal of Drug Policy, 14, 399-405. 
MCVEIGH, J. & EVANS-BROWN, M. 2009. Anabolic Steroids. 
MCVEIGH, J., EVANS-BROWN, M. & BELLIS, M. A. 2012a. Human enhancement drugs and 
the pursuit of perfection. ADICCIONES, 24, 185-190. 
MCVEIGH, J., EVANS-BROWN, M. & MARK, B. 2012b. Human enhancement drugs and the 
pursuit of perfection. Adicciones, 24, 185-190. 
MCVEIGH, J., GERMAIN, J. & VAN HOUT, M. C. 2016a. 2, 4-Dinitrophenol, the inferno drug: a 
netnographic study of user experiences in the quest for leanness. Journal of 
Substance Use, 1-8. 
72 
 
MCVEIGH, J., GERMAIN, J. & VAN HOUT, M. C. 2017a. 2,4-Dinitrophenol, the inferno drug: a 
netnographic study of user experiences in the quest for leanness. Journal of 
Substance Use, 22, 131-138. 
MCVEIGH, J., HEARNE, E., BATES, G. & VAN HOUT, M. C. 2017b. Community pharmacist 
experiences of providing needle and syringe programmes in Ireland. Res Social Adm 
Pharm, 13, 767-777. 
MCVEIGH, J., HUGHES, K., HOUNSOME, J. & BELLIS, M. 2003b. Over a decade of drug use 
Epidemiology. Centre for Public Health: Liverpool John Moores University. 
MCVEIGH, J., KIMERGARD, A., BATES, G. & HOPE, V. 2016b. Harm reduction interventions 
should encompass people who inject image and performance enhancing drugs. 
MCVEIGH, J. & LENEHAN, P. 1994. Counterfeits and fakes: a growing problem. Relay, 1, 8-9. 
MELIA, P., PIPE, A. & GREENBERG, L. 1996. The Use of Anabolic-Androgenic Steroids by 
Canadian Students. Clinical Journal of Sport Medicine, 6, 9-14. 
METASTASIO, A., NEGRI, A., MARTINOTTI, G. & CORAZZA, O. 2018. Transitioning Bodies. The 
Case of Self-Prescribing Sexual Hormones in Gender Affirmation in Individuals 
Attending Psychiatric Services. Brain Sciences, 8. 
MIDDLEMAN, A. B., FAULKNER, A. H., WOODS, E. R., EMANS, S. J. & DURANT, R. H. 1995. 
High-Risk Behaviors among High-School-Students in Massachusetts Who Use 
Anabolic-Steroids. Pediatrics, 96, 268-272. 
MIDGLEY, S. J., HEATHER, N., BEST, D., HENDERSON, D., MCCARTHY, S. & DAVIES, J. B. 2000. 
Risk behaviours for HIV and hepatitis infection among anabolic-androgenic steroid 
users. Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv, 12, 163-170. 
MILLAR, A. P. 1994. Licit steroid use--hope for the future. Br J Sports Med, 28, 79-83. 
MILLAR, A. P. 1996. Anabolic Steroids - A Personal Piilgramage. Journal of Performance 
Enhancing Drugs, 1, 4-9. 
MILLAR, A. P. 1998. Anabolic Steroids and Weight Change. The Journal of Performance 
Enhancing Drugs, 2, 4-15. 
MOCHIZUKI, R. M. & RICHTER, K. J. 1988. Cardiomyopathy and Cerebrovascular Accident 
Associated With Anabolic-Androgenic Steroid Use. Phys Sportsmed, 16, 109-14. 
MONAGHAN, L. 1999. Challenging medicine? Bodybuilding, drugs and risk. Sociology of 
Health & Illness, 21, 707-734. 
MONAGHAN, L. F. 2002. Vocabularies of motive for illicit steroid use among bodybuilders. 
Social Science & Medicine, 55, 695-708. 
MORRISON, C. L. 1994. Anabolic steroid users identified by needle and syringe exchange 
contact. Drug Alcohol Depend, 36, 153-5. 
MUSSHOFF, F., DALDRUP, T. & RITSCH, M. 1997. Black market in anabolic steroids - Analysis 
of illegally distributed products. Journal of Forensic Sciences, 42, 1119-1125. 
NAKHAEE, R. M., PAKRAVAN, F. & NAKHAEE, N. 2013. Prevalence of use of anabolic steroids 
by bodybuilders using three methods in a city of Iran. Addict Health, 5, 77-82. 
NATIONAL ADVISORY COMMITTEE ON  DRUGS 2012. Drug use in Ireland and Northern 
Ireland. Drug prevalence survey 2010/11: Dublin & Belfast. Public Health Information 
and Research Branch. Dublin. 
NICE 2009. NICE guidance on optimal provision of NSP. London: NICE. 
NICE 2014. Needle and syringe programmes NICE public health guidance. NICE: National 
Institute for Health and Care Excellence. 
NICE 2017. Drug misuse prevention: targeted interventions (NG64). London: NICE. 
73 
 
NIESCHLAG, E. & BEHRE, H. M. 2004. Testosterone: action, deficiency and substitution, 
Cambridge, UK, Cambridge University Press. 
NIESCHLAG, E., BEHRE, H. M., BOUCHARD, P., CORRALES, J. J., JONES, T., STALLA, G. K., 
WEBB, S. M. & WU, F. C. 2004. Testosterone replacement therapy: current trends 
and future directions. Hum Reprod Update, 10, 409-19. 
NILSSON, S. 1995. Androgenic anabolic steroid use among male adolescents in Falkenberg. 
European Journal of Clinical Pharmacology, 48. 
O'REGAN, E. 2017a. Gardai seize 60,000 vials of anabolic steroids worth €2m. Irish 
Independent, 9/3/2017. 
O'REGAN, M. 2017b. Steroid abuse rises sharply amongst middle-aged men. Irish 
Independent, 31/12/2017. 
OVERLY, W. L., DANKOFF, J. A., WANG, B. K. & SINGH, U. D. 1984. Androgens and 
hepatocellular carcinoma in an athlete. Ann Intern Med, 100, 158-9. 
PAMPEL, F. C. 2007. Drugs and Sport, New York, Facts on File. 
PANG, L. 2008. `China Who Makes and Fakes': A Semiotics of the Counterfeit. Theory, 
Culture & Society, 25, 117-140. 
PARISH, T., BAGHURST, T. & TURNER, T. 2010. Becoming Competitive Amateur 
Bodybuilders: Identification of Contributors. Psychology of Men & Masculinity, 11, 
152–159. 
PARROTT, A. C., CHOI, P. Y. L. & DAVIES, M. 1994. Anabolic-Steroid Use by Amateur Athletes 
- Effects Upon Psychological Mood States. Journal of Sports Medicine and Physical 
Fitness, 34, 292-298. 
PATES, R. & BARRY, C. 1996. Steroid use in Cardiff: A problem for whom? The Journal of 
Peformance Enhancing Drugs, 1, 92-97. 
PEARSON, D. E. 1967. Body building by drugs. Br Med J, 4, 353. 
PERRY, H. 1995. Counterfeit—fake anabolic steroids and hazards of their use. Relay, 1, 9-12. 
PERRY, H., EVANS, A. H. & LITTLEPAGE, B. N. C. 1994. Anabolic steroids what do GPs think. 
International Journal of Drug Policy, 5, 15-17. 
PERRY, H. & HUGHES, G. 1992. A case of affective disorder associated with the misuse 
of'anabolic steroids'. British journal of sports medicine, 26, 219-220. 
PERRY, H. M. & LITTLEPAGE, B. N. C. 1992. Misusing anabolic drugs. BMJ, 305, 1241-1242. 
PERRY, H. M., WRIGHT, D. & LITTLEPAGE, B. N. 1992. Dying to be big: a review of anabolic 
steroid use. Br J Sports Med, 26, 259-61. 
PHE. 2014. Services for image and performance enhancing drug (IPED) users: turning 
evidence into practice [Online]. London: Gov.UK. Available: 
https://www.gov.uk/government/publications/treating-substance-misuse-and-
related-harm-turning-evidence-into-practice/services-for-image-and-performance-
enhancing-drug-iped-users-turning-evidence-into-practice#fn:15 [Accessed 28/01/18 
2018]. 
PHILLIPS, W. N. 1991. Anabolic reference guide. Golden, CO, U.S.A.: Mile High Pub. 
POPE, H. G., JR., KANAYAMA, G., ATHEY, A., RYAN, E., HUDSON, J. I. & BAGGISH, A. 2014a. 
The lifetime prevalence of anabolic-androgenic steroid use and dependence in 
Americans: current best estimates. Am J Addict, 23, 371-7. 
POPE, H. G. & KANAYAMA, G. 2012. Anabolic–Androgenic Steroids. Drug Abuse and 
Addiction in Medical Illness. Springer Science + Business Media. 
POPE, H. G. & KATZ, D. L. 1990. Homicide and near-Homicide by Anabolic-Steroid Users. 
Journal of Clinical Psychiatry, 51, 28-31. 
74 
 
POPE, H. G. & KATZ, D. L. 1992. Psychiatric Effects of Anabolic-Steroids. Psychiatric Annals, 
22, 24-29. 
POPE, H. G. & KATZ, D. L. 1994. Psychiatric and medical effects of anabolic-androgenic 
steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry, 51. 
POPE, H. G., KATZ, D. L. & CHAMPOUX, R. 1988. Anabolic-Androgenic Steroid Use among 
1,010 College Men. Physician and Sportsmedicine, 16, 75-&. 
POPE, H. G., KHALSA, J. H. & BHASIN, S. 2016. Body Image Disorders and Abuse of Anabolic-
Androgenic Steroids Among Men. JAMA. 
POPE, H. G., KOURI, E. M. & HUDSON, J. I. 2000. Effects of supraphysiologic doses of 
testosterone on mood and aggression in normal men - A randomized controlled trial. 
Archives of General Psychiatry, 57, 133-140. 
POPE, H. G., WOOD, R. I., ROGOL, A., NYBERG, F., BOWERS, L. & BHASIN, S. 2014b. Adverse 
Health Consequences of Performance-Enhancing Drugs: An Endocrine Society 
Scientific Statement. Endocrine Reviews, 35, 341-375. 
PRAT, J., GRAY, G. F., STOLLEY, P. D. & COLEMAN, J. W. 1977. Wilms tumor in an adult 
associated with androgen abuse. JAMA, 237, 2322-3. 
PUBLIC HEALTH ENGLAND 2015. Providing effective services for people who use image and 
performance enhancing drugs. London: PHE Publications. 
RHODES, T. 2002. The ‘risk environment’: a framework for understanding and 
reducing drug-related harm. International Journal of Drug Policy, 13, 85 - 94. 
RHODES, T. 2009. Risk environments and drug harms: a social science for harm reduction 
approach. Int J Drug Policy, 20, 193-201. 
RICH, J. D., DICKINSON, B. P., FELLER, A., PUGATCH, D. & MYLONAKIS, E. 1999a. The 
infectious complications of anabolic-androgenic steroid injection. Int J Sports Med, 
20, 563-6. 
RICH, J. D., DICKINSON, B. P., FLANIGAN, T. P. & VALONE, S. E. 1999b. Abscess related to 
anabolic-androgenic steroid injection. Med Sci Sports Exerc, 31, 207-9. 
RICH, J. D., DICKINSON, B. P., MERRIMAN, N. A. & FLANIGAN, T. P. 1998a. Hepatitis C virus 
infection related to anabolic-androgenic steroid injection in a recreational weight 
lifter. Am J Gastroenterol, 93, 1598. 
RICH, J. D., DICKINSON, B. P., MERRIMAN, N. A. & THULE, P. M. 1998b. Insulin use by 
bodybuilders. JAMA, 279, 1613. 
ROGERS, E. M. 1983. Diffusion of innovations, New York, The Free Press. 
ROGERS, E. M. 1995. Diffusion of drug abuse prevention programs: spontaneous diffusion, 
agenda setting, and reinvention. In: BACKER, T. E., DAVID, S. L. & SOUCY, G. P. (eds.) 
Reviewing the behavioral science knowledge base on technology transfer. Rockville, 
MD: United States Government Printing. 
SAGOE, D., ANDREASSEN, C. S., MOLDE, H., TORSHEIM, T. & PALLESEN, S. 2014a. Prevalence 
and Correlates of Anabolic–Androgenic Steroid Use in a Nationally Representative 
Sample of 17-Year-Old Norwegian Adolescents. Substance Use & Misuse, 50, 139-
147. 
SAGOE, D., ANDREASSEN, C. S. & PALLESEN, S. 2014b. The aetiology and trajectory of 
anabolic-androgenic steroid use initiation: a systematic review and synthesis of 
qualitative research. Substance Abuse Treatment Prevention and Policy, 9. 
SAGOE, D., MCVEIGH, J., BJORNEBEKK, A., ESSILFIE, M. S., ANDREASSEN, C. S. & PALLESEN, S. 
2015a. Polypharmacy among anabolic-androgenic steroid users: a descriptive 
metasynthesis. Substance Abuse Treatment Prevention and Policy, 10, 12. 
75 
 
SAGOE, D., MOLDE, H., ANDREASSEN, C. S., TORSHEIM, T. & PALLESEN, S. 2014c. The global 
epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-
regression analysis. Annals of Epidemiology, 24, 383-398. 
SAGOE, D. & PALLESEN, S. 2018. Androgen abuse epidemiology. Curr Opin Endocrinol 
Diabetes Obes. 
SAGOE, D., TORSHEIM, T., MOLDE, H., ANDREASSEN, C. S. & PALLESEN, S. 2015b. Anabolic-
androgenic steroid use in the Nordic countries: A meta-analysis and meta-regression 
analysis. Nordic Studies on Alcohol and Drugs, 32, 7-20. 
SANTOS, A. M., DA ROCHA, M. S. P. & DA SILVA, M. F. 2010. Illicit Use and Abuse of 
Anabolic-Androgenic Steroids Among Brazilian Bodybuilders. Substance Use & 
Misuse, 46, 742-748. 
SAVULESCU, J., SANDBERG, A. & KAHANE, G. 2011. Well-being and enhancement. In: J 
SAVELESCU, R. T. M., G KAHANE (ed.) Enhancing human capacities. Oxford: Wiley-
Blackwell. 
SCALLY, M. C. & TAN, R. S. 2009. Complexities in clarifying the diagnostic criteria for 
anabolic-androgenic steroid dependence. Am J Psychiatry, 166, 1187; author reply 
1188. 
SCHIFANO, F., RICCIARDI, A., CORAZZA, O., DELUCA, P., DAVEY, Z., RAFANELLI, C. & 
MAPPING, G. R. P. W. 2010. New drugs and role of the web: Psychonaut Web 
Mapping Project. Rivista Di Psichiatria, 45, 88-93. 
SCHNETZLER, G., BANKS, I., KIRBY, M., ZOU, K. H. & SYMONDS, T. 2010. Characteristics, 
Behaviors, and Attitudes of Men Bypassing the Healthcare System When Obtaining 
Phosphodiesterase Type 5 Inhibitors. Journal of Sexual Medicine, 7, 1237-1246. 
SCOTT, M. J. & SCOTT, M. J. 1989. Hiv Infection Associated with Injections of Anabolic-
Steroids. Jama-Journal of the American Medical Association, 262, 207-208. 
SEITZ, J., LYALL, A. E., KANAYAMA, G., MAKRIS, N., HUDSON, J. I., KUBICKI, M., POPE JR, H. G. 
& KAUFMAN, M. J. 2017. White matter abnormalities in long-term anabolic-
androgenic steroid users: A pilot study. Psychiatry Research: Neuroimaging, 260, 1-5. 
SIVA, N. 2010. Tackling the booming trade in counterfeit drugs. Lancet, 376, 1725-1726. 
SKLAREK, H. M., MANTOVANI, R. P., ERENS, E., HEISLER, D., NIEDERMAN, M. S. & FEIN, A. M. 
1984. Aids in a Bodybuilder Using Anabolic-Steroids. New England Journal of 
Medicine, 311, 1701-1701. 
STENSBALLE, A., MCVEIGH, J., BREINDAHL, T. & KIMERGARD, A. 2015. Synthetic growth 
hormone releasers detected in seized drugs: new trends in the use of drugs for 
performance enhancement. Addiction, 110, 368-9. 
STILGER, V. G. & YESALIS, C. E. 1999. Anabolic-androgenic steroid use among high school 
football players. Journal of Community Health, 24, 131-145. 
STIMSON, G. V. 1995. AIDS and drug injecting in the United Kingdom 1987 - 1993:the policy 
response to the prevention of the epidemic. Social Science and Medicine, 41, 699-
716. 
STIMSON, G. V. 1996. Has the United Kingdom averted an epidemic of HIV-1 infection 
among drug injectors? Addiction, 91, 1085-8; discussion 1089-99. 
STRAUSS, R. H., LIGGETT, M. T. & LANESE, R. R. 1985. Anabolic steroid use and perceived 
effects in ten weight-trained women athletes. JAMA, 253. 
STUBBE, J. H., CHORUS, A. M. J., FRANK, L. E., DE HON, O. & VAN DER HEIJDEN, P. G. M. 
2014. Prevalence of use of performance enhancing drugs by fitness centre members. 
Drug Testing and Analysis, 6, 434-438. 
76 
 
SU, T. P., PAGLIARO, M., SCHMIDT, P. J., PICKAR, D., WOLKOWITZ, O. & RUBINOW, D. R. 
1993. Neuropsychiatric Effects of Anabolic-Steroids in Male Normal Volunteers. 
Jama-Journal of the American Medical Association, 269, 2760-2764. 
SUMNALL, H. R., EVANS-BROWN, M. & MCVEIGH, J. 2011. Social, policy, and public health 
perspectives on new psychoactive substances. Drug Test Anal, 3, 515-23. 
SYMPLECTIC. 2018. Symplectic Elements [Online]. Symplectic. Available: 
https://symplectic.ljmu.ac.uk/default.html [Accessed 1/12/2018]. 
TAINTER, M. L., CUTTING, W. C. & STOCKTON, A. B. 1934. Use of Dinitrophenol in Nutritional 
Disorders : A Critical Survey of Clinical Results. Am J Public Health Nations Health, 24, 
1045-53. 
TAN, R. S. & SCALLY, M. C. 2009. Anabolic steroid-induced hypogonadism--towards a unified 
hypothesis of anabolic steroid action. Med Hypotheses, 72, 723-8. 
TAYLOR, W. N. 1991. Macho medicine, Jefferson, NC, McFarland and Company. 
TAYLOR, W. N. 2001. Anabolic Steroids and the Athlete, Jefferson, NC, MacFarland and 
Company Inc. Publishers. 
THIBLIN, I., GARMO, H., GARLE, M., HOLMBERG, L., BYBERG, L., MICHAELSSON, K. & 
GEDEBORG, R. 2015. Anabolic steroids and cardiovascular risk: A national 
population-based cohort study. Drug and Alcohol Dependence, 152, 87-92. 
TILL, K., JONES, B., MCKENNA, J., WHITAKER, L. & BACKHOUSE, S. H. 2016. The search for 
size: a doping risk factor in adolescent rugby? British Journal of Sports Medicine, 50, 
203-204. 
TODD, T. 1987. Anabolic-Steroids - the Gremlins of Sport. Journal of Sport History, 14, 87-
107. 
TOMIC, S., MILCIC, N., SOKOLIC, M. & MARTINAC, A. I. 2010. Identification of counterfeit 
medicines for erectile dysfunction from an illegal supply chain. Arh Hig Rada 
Toksikol, 61, 69-75. 
TUITE, T. 2017. Gym instructor selling anabolic steroids through Facebook, court told. Irish 
Independent, 24/10/2017. 
TUTTLE, L. A., GAA, G. A., GRIFFITH, E. H. & CAHILL, B. R. 1994. Prevalence of anabolic 
steroid use among illinois high school students. J Athl Train, 29, 216-22. 
UNDERWOOD, M. In press. The unintended consequences of the current approach to blood 
borne virus prevention amongst people who inject image and performance 
enhancing drugs: A commentary based on enhanced bodybuilder perspectives. 
International Journal of Drug Policy. 
UNODC 2015. International Standards on Drug Use Prevention. Vienna: United Nations on 
Drugs and Crime. 
VAN DE VEN, K. & KOENRAADT, R. 2017. Exploring the relationship between online buyers 
and sellers of image and performance enhancing drugs (IPEDs): Quality issues, trust 
and self-regulation. Int J Drug Policy, 50, 48-55. 
VAN HOUT, M. C. & HEARNE, E. 2016. Netnography of Female Use of the Synthetic Growth 
Hormone CJC-1295: Pulses and Potions. Substance Use & Misuse, 51, 73-84. 
VAN HOUT, M. C. & KEAN, J. 2015. An exploratory study of image and performance 
enhancement drug use in a male British South Asian community. The International 
journal of drug policy, 26, 860-7. 
VOY, V. 1991. Drugs, sport and politics, IL, Leisure Press. 
WALSH, H. 2017. Illegal steroid factory uncovered in Donegal. Donegal News, 30/11/2017. 
77 
 
WARNER, K. E. & BOAT, T. F. 2009. Preventing Mental, Emotional, and Behavioral Disorders 
Among Young People Progress and Possibilities Preface. Preventing Mental, 
Emotional, and Behavioral Disorders among Young People: Progress and Possibilities, 
Xiii-+. 
WESTLYE, L. T., KAUFMANN, T., ALNAES, D., HULLSTEIN, I. R. & BJORNEBEKK, A. 2017. Brain 
connectivity aberrations in anabolic-androgenic steroid users. Neuroimage Clin, 13, 
62-69. 
WHITEHEAD, R., CHILLAG, S. & ELLIOTT, D. 1992. Anabolic-Steroid Use among Adolescents in 
a Rural State. Journal of Family Practice, 35, 401-405. 
WHITFIELD, M., REED, H., LEECH, C., HARRISON, B. & MCVEIGH, J. 2017. Integrated 
Monitoring System Annual Report: Cheshire and Merseyside 2016/17. Liverpool: 
Liverpool John Moores University. 
WILLIAMSON, D. 1991. Anabolic-Steroid Use Outside Competition. British Journal of 
Psychiatry, 159, 161-161. 
WILLIAMSON, D. J. 1993. Anabolic steroid use among students at a British college of 
technology. British Journal of Sports Medicine, 27, 200-201. 
WINSTOCK, A., LYNSKEY, M., BORSCHMANN, R. & WALDRON, J. 2015. Risk of emergency 
medical treatment following consumption of cannabis or synthetic cannabinoids in a 
large global sample. J Psychopharmacol, 29, 698-703. 
WRIGHT, J. E. 1978. Anabolic Steroids and Sports, Natick, MA, Sports Science Consultants. 
WRIGHT, J. E. 1982. Anabolic Steroids and Sports: Volume II, Natick, MA, Sports Science 
Consultants. 
YESALIS, C. E. 1992. Epidemiology and Patterns of Anabolic-Androgenic Steroid Use. 
Psychiatric Annals, 22, 7-8. 
YESALIS, C. E. & BAHRKE, M. S. 1995. Anabolic-Androgenic Steroids. Sports Medicine, 19, 
326-340. 
YESALIS, C. E. & BAHRKE, M. S. 2002. Anabolic-androgenic steroids and related substances. 
Curr Sports Med Rep, 1, 246-52. 
YESALIS, C. E., BAHRKE, M. S., KOPSTEIN, A. N. & BARSUKIEWICZ, C. K. 2000a. Incidence of 
anabolic steroid use: a discussion of methodological issues. In: YESALIS, C. E. (ed.) 
Anabolic steroids in sport and exercise. 2 ed. Champaign, IL: Human Kinetics. 
YESALIS, C. E., BARSUKIEWICZ, C. K., KOPSTEIN, A. N. & BAHRKE, M. S. 1997. Trends in 
anabolic-androgenic steroid use among adolescents. Arch Pediatr Adolesc Med, 151. 
YESALIS, C. E., COURSON, S. P. & WRIGHT, J. E. 2000b. History of use in sport and exercise. 
In: YESALIS, C. E. (ed.) Anabolic steroids in Sport and Exercise. 2 ed. Champaign, IL: 
Human Kinetics. 
YESALIS, C. E., WRIGHT, J. E. & BAHRKE, M. S. 1989. Epidemiological and policy issues in the 
measurement of the long term health effects of anabolic-androgenic steroids. Sports 
Med, 8, 129-38. 
YESALIS, C. E., WRIGHT, J. E. & LOMBARDO, J. A. 1993. Anabolic steroids in athletes. In: 
KOPERA, H. (ed.) Anabolic-androgenic steroids: towards the year 2000. Wien, 
Austria: Blackwell-MZV. 
YOSHIDA, E. M., KARIM, M. A., SHAIKH, J. F., SOOS, J. G. & ERB, S. R. 1994. At What Price, 
Glory - Severe Cholestasis and Acute-Renal-Failure in an Athlete Abusing Stanozolol. 
Canadian Medical Association Journal, 151, 791-793. 
78 
 
ZAHNOW, R., MCVEIGH, J., BATES, G., HOPE, V., KEAN, J., CAMPBELL, J. & SMITH, J. 2018. 
Identifying a typology of men who use anabolic androgenic steroids (AAS). Int J Drug 
Policy, 55, 105-112. 
ZAHNOW, R., MCVEIGH, J., FERRIS, J. & WINSTOCK, A. 2017. Adverse Effects, Health Service 
Engagement, and Service Satisfaction Among Anabolic Androgenic Steroid Users. 
Contemporary Drug Problems, 44, 69-83. 
ZINBERG, N. E. 1984. Drug, set and setting, New Haven: Yale University. 
 
Appendix I: Submitted Papers 
 
1) Zahnow, R., McVeigh, J., Bates, G., Hope, V., Kean, J., Campbell, J., & Smith, J. (2018) 
Identifying a typology of men who use Anabolic Androgenic Steroids (AAS). International 
Journal of Drug Policy. 55, 105-112 
 
2) McVeigh, J., & Begley, E. (2017). Anabolic steroids in the UK: an increasing issue for public 
health. Drugs: Education, Prevention and Policy, 24:3, 278-285  
 
3) Zahnow, R., McVeigh, J., Ferris, J., & Winstock, A. (2017). Adverse effects, health service 
engagement, and service satisfaction among anabolic androgenic steroid users. 
Contemporary Drug Problems 44(1):69-83 01  
 
4) McVeigh, J., Germain, J., & Van Hout, M. C. (2016). 2,4-Dinitrophenol, the inferno drug: a 
netnographic study of user experiences in the quest for leanness. Journal of Substance Use, 
22(2), 131-138.  
 
5) McVeigh, J., Hearne, E., Bates, G., & Van Hout, M. C. (2016). Community pharmacist 
experiences of providing needle and syringe programmes in Ireland. Research in Social and 
Administrative Pharmacy. S1551-7411(16)30310-2  
 
6) Kimergard, A., & McVeigh, J. (2014). Environments, risk and health harms: a qualitative 
investigation into the illicit use of anabolic steroids among people using harm reduction 
services in the UK. BMJ Open, 4(6), 7 pages. doi:10.1136/bmjopen-2014-005275 
 
7) Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., 
Croxford S., Beynon C. M., Parry J. V., Bellis, M. A. & Ncube F. (2013).  Prevalence of, and risk 
factors for, HIV, hepatitis B and C infections among men who inject image and performance 
enhancing drugs: a cross-sectional study. BMJ OPEN, 3(9),  
 
8) McVeigh, J., Beynon, C., & Bellis, M. A. (2003). New challenges for agency based syringe 
exchange schemes: Analysis of 11 years of data (1991-2001) in Merseyside and Cheshire, 
United Kingdom. International Journal of Drug Policy, 14(5-6), 399-405.  
 Appendix II: Supplemental material 
 
Appendix II.1 Supplemental peer-reviewed journal papers 
 
9) Bates, G., Tod, D., Leavey, C., & McVeigh, J. (2018). An evidence-based socioecological 
framework to understand men’s use of anabolic androgenic steroids and inform 
interventions in this area. Drugs: Education, Prevention, and Policy. 
Journal Impact Factor 0.94 Citations -  Altmetric 17 
Contribution: Last author responsible for co-conception of study, co-development of 
methodology, co-analysis and 25% writing of paper. Guarantor of paper 
 
10) Hope, VD, McVeigh, J Smith, J. Glass, R, Njoroge, J, Tanner, C, Parry, JV, Ncube, F, Desai 
M (2017) Low levels of hepatitis C diagnosis and testing uptake among people who inject 
image and performance enhancing drugs in England and Wales, 2012-15 Drug and Alcohol 
Dependence Volume 179, Pages 83–86 
Journal Impact Factor 3.22 Citations –  Altmetric 26 
Contribution: Second author responsible for co-conception of study, co-development of 
methodology, co-analysis and 30% writing of paper. 
 
11) Hope, V. D., Harris, R., McVeigh, J., Cullen, K. J., Smith, J., Parry, J. V., . . . Ncube, F. 
(2016). Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and 
Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional 
Prevalence Surveys, 1992-2013. JAIDS-Journal of Acquired Immune Deficiency Syndrome, 
71(3), 331-337. 
Journal Impact Factor 3.9 Citations 6 Altmetric 4 
Contribution: Co- author responsible for co-conception of study, co-development of 
methodology, and 30% writing of paper. 
 
12) Sagoe, D., McVeigh, J., Bjornebekk, A., Essilfie, M. -S., Andreassen, C. S., & Pallesen, S. 
(2015). Polypharmacy among anabolic-androgenic steroid users: a descriptive 
metasynthesis. Substance Abuse Treatment Prevention and Policy, 10, 19 pages. 
Journal Impact Factor 1.81 Citations 31 Altmetric 10 
Contribution: Second author responsible for co-conception of study, co-development of 
methodology, co-analysis and 35% writing of paper. 
 
13) Breindahl, T., Evans-Brown, M., Hindersson, P., McVeigh, J., Bellis, M., Stensballe, A., & 
Kimergard, A. (2015). Identification and characterization by LC-UV-MS/MS of melanotan II 
skin-tanning products sold illegally on the Internet. Drug Testing and Analysis, 7(2), 164-172. 
Journal Impact Factor 3.47 Citations 16 Altmetric 7 
Contribution: Co-author responsible for co-conception of study, co-development of 
methodology and 20% writing of paper. 
 
14) Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., Parry 
J. V. &  Ncube, F. (2015). Injection site infections and injuries in men who inject image- and 
performance-enhancing drugs: prevalence, risks factors, and healthcare seeking. 
Epidemiology and Infection, 143(1), 132-140. 
Journal Impact Factor 2.08 Citations 9 Altmetric 7 
 Contribution: Second author responsible for co-conception of study, co-development of 
methodology, co-analysis and 30% writing of paper. 
 
15) Abbate, V., Kicman, A. T., Evans-Brown, M., McVeigh, J., Cowan, D. A., Wilson, C., . . . 
Walker, C. J. (2015). Anabolic steroids detected in bodybuilding dietary supplements - a 
significant risk to public health. Drug Testing and Analysis, 7(7), 609-618. 
Journal Impact Factor 3.47 Citations 30 Altmetric 179 
Contribution: Co- author responsible for co-conception of study, co-development of 
methodology, co-analysis and 35% writing of paper. 
 
16) Kimergard, A., & McVeigh, J. (2014). Variability and dilemmas in harm reduction for 
anabolic steroid users in the UK: a multi-area interview study. Harm reduction Journal, 11, 
13 pages 
Journal Impact Factor 1.88 Citations 17  Altmetric 20 
Contribution: Second author responsible for co-conception of study, co-development of 
methodology, co-analysis and 45% writing of paper and guarantor of paper. 
 
 
 
Appendix II.2 Additional peer-reviewed journal papers, editorials, systematic reviews 
 
17) Bates, G., Begley, E., Tod, D., Jones, L., Leavey, C., & McVeigh, J. (2017). A systematic 
review investigating the behaviour change strategies in interventions to prevent misuse of 
anabolic steroids. Journal of Health Psychology, 1359105317737607 
Journal Impact Factor 2.18 Citations 1  Altmetric 11 
Contribution: Co-author responsible for co-conception of study, co-development of 
methodology, 20% writing and guarantor of paper. 
 
18) McVeigh, J., Kimergard, A., Bates, G., Hope, V., & Ncube, F. (2006). Focus on harm 
reduction in fight against HIV, says report. BMJ-British Medical Journal. 
Journal Impact Factor 20.79 
Contribution: Principle author responsible for conception and writing of paper. 
 
19) Iversen, J., Hope, V. D., & McVeigh, J. (2016). Access to needle and syringe programs by 
people who inject image and performance enhancing drugs. International Journal of Drug 
Policy, 31, 199-200 
Journal Impact Factor 3.48 Citations 5  Altmetric 6 
Contribution: Co-author responsible for co-conception and co-writing paper and guarantor 
of paper. 
 
20) Stensballe, A., McVeigh, J., Breindahl, T., & Kimergard, A. (2015) Synthetic Growth 
Hormone releasers detected in seized drugs: New trends in the use of performance 
enhancement. Addiction, 110(2), 368-369 
Journal Impact Factor 5.79 Citations 5 Altmetric 7 
Contribution: Second author responsible for co-conception of study, co-development of 
methodology, co-analysis and 25% writing of paper. 
 
 21) Kimergard, A., Breindahl, T., Hindersson, P., & McVeigh, J. (2014). The composition of 
anabolic steroids from the illicit market is largely unknown: implications for clinical case 
reports. QJM-An International Journal of Medicine, 107(7), 597-598. 
Journal Impact Factor 3.13 Citations 5 Altmetric 5 
Co- author responsible for co-conception of study, co-development of methodology, co-
analysis and 20% writing of paper and guarantor of paper 
 
22) Kimergard, A., McVeigh, J., Knutsson, S., Breindahl, T., & Stensballe, A. (2014). Online 
marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges 
to public health. Drug testing and Analysis, 6(4), 396-398. 
Journal Impact Factor 3.47 Citations – Altmetric 5 
Second- author responsible for co-conception of study, co-development of methodology, 
co-analysis and 20% writing of paper. 
 
23) Evans-Brown, M., Kimergard, A., McVeigh, J., Chandler, M., & Brandt, S. D. (2014). 
Bodybuilding Supplements: Is the breast cancer drug tamoxifen being sold as a bodybuilding 
dietary supplement? BMJ-British Medical Journal, 348, 2 pages. 
Journal Impact Factor 20.79 Citations 10 Altmetric 85 
Co-author responsible for co-conception of study, co-development of methodology, co-
analysis and 20% writing of paper. 
 
24) Hope, V., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergard, A., . . . 
Ncube, F. (2013). Prevalence of, and risk factors for, human immunodeficiency virus, 
hepatitis B and hepatitis C infections among men who inject image- and performance-
enhancing drugs in England & Wales. HIV MEDICINE, 14, 2. 
Journal Impact Factor 3.26 Citations -  Altmetric –  
Contribution: Second author responsible for co-conception of study, co-development of 
methodology and 35% writing of paper. 
 
25) McVeigh, J., Evans-Brown, M., & Bellis, M. A. (2012). Human enhancement drugs and 
the pursuit of perfection. Adicciones, 24(3), 185-190. 
Journal Impact Factor 2.08 Citations  18 Altmetric –  
Contribution: Principle author responsible for conception of study, development of 
methodology, co-analysis and writing of paper. 
 
26) Jones, L., Pickering, L., Sumnall, H., McVeigh, J., & Bellis, M. A. (2010). Optimal provision 
of needle and syringe programmes for injecting drug users: A systematic review. 
International Journal of Drug Policy, 21(5), 335-342. 
Journal Impact Factor 3.48 Citations  9 Altmetric  6 
Contribution: Co-author responsible for co-conception of study, co-development of 
methodology, co-analysis and 20% writing of paper. 
 
27) Evans-Brown, M., Dawson, R. T., Chandler, M., & McVeigh, J. (2009). Use of melanotan I 
and II in the general population. British Medical Journal, 338, 3 pages.  
Journal Impact Factor 20.79 Citations  29 Altmetric  19 
Contribution: Co-author responsible for co-conception of study, 30% of writing and 
guarantor of paper. 
  
28) Evans-Brown, M., Kimergard, A. & McVeigh, J. (2009) Elephant in the room? The 
methodological implications for public health research of performance-enhancing drugs 
derived from the illicit market. Drug Testing and Analysis 1(7-8):323-326 
Journal Impact Factor 3.47 Citations  18 Altmetric  19 
Co-author responsible for co-conception of study, co-development of methodology, co-
analysis, 40% of writing and guarantor of paper. 
 
29) Evans-Brown, M., & McVeigh, J. (2009) Injecting human growth hormone as a 
performance-enhancing drug-perspectives from the United Kingdom. Journal of Substance 
Use 14(5):267-288 
Journal Impact Factor 0.77 Citations  10 Altmetric  1 
Second author responsible for co-conception of study, 40% of writing and guarantor of 
paper. 
30) Evans-Brown, M., Dawson, R., & McVeigh, J. (2008). The dire consequences of doping? 
Lancet, 372(9649), 1544. 
Journal Impact Factor 47.83   
Co-author responsible for co-conception of study, 30% of writing and guarantor of paper. 
 
 
Appendix II.3 Selected minor peer reviewed papers, reports and book chapters 
 
31) Chester, N., & McVeigh, J. (2018). Drug Use in Society and the Impact on the Anti-
Doping Movement. In D. R. Mottram, & N. Chester (Eds.), Drugs in Sport. London: 
Routledge. 
 
32) Bates, G., Hope, V., & McVeigh, J. (2017). HIV among people using anabolic steroid in 
the United Kingdom: an overview. HIV Nursing, 17(1), 20-23 
 
33) Begley, E., McVeigh, J., Hope, V. D., Bates, G., Glass, R., Campbell, J., . . . Smith, J. (2017). 
Image and Performance Enhancing Drugs 2016 National Survey Results: Image and 
Performance Enhancing Drugs 2016 National Survey Results. Public Health Institute, 
Liverpool John Moores University. 
 
34) Bates, G., & McVeigh, J. (2016). Image and Performance Enhancing Drugs 2015 Survey 
Results. Liverpool: Liverpool John Moores University.  
 
35) McVeigh, J., Bates, G., & Chandler, M. (2015). Steroids and Image Enhancing Drugs 2014 
Survey Results. Liverpool John Moores University. 
 
36) Bates, G., Van Hout, M. C., Hearne, E., Mackridge, A., McVeigh, J. (2015) Evaluation of 
the pilot stage of the Pharmacy Needle Exchange Programme in Ireland. Liverpool: Centre 
for Public Health, Liverpool John Moores University. 
 
37) Bates, G., Jones, L., & McVeigh, J. (2013). Update of NICE Guidance PH18 on 'Needle and 
Syringe programmes. PIEDs Review. Centre for Public Health, Liverpool John Moores 
University.  
  
38) Evans-Brown, M., McVeigh, J., Perkins, C., & Bellis, M. A. (2012). Human Enhancement 
Drugs - The Emerging Challenges to Public Health: Human Enhancement Drugs - The 
Emerging Challenges to Public Health. Liverpool: Centre for Public Health, Liverpool John 
Moores University. 
 
39) Evans-Brown, M., McVeigh, J Anabolic steroid use in the general population of the 
United Kingdom In Elite Sport, Doping and Public Health. Editors: Dimeo P, McNamee M, 
Moller V. (2009) 75-97 (22 pages). Univ Pr of Southern Denmark. 
 
40) Jones, L., Pickering, L., Sumnall, H., McVeigh, J., & Bellis, M. (2008). A review of the 
effectiveness and cost-effectiveness of needle and syringe programmes for injecting drug 
users. Centre for Public Health, Liverpool John Moores University 
 
41) Jones, L., Bates, G., Beynon, C., Duffy, P., Evans-Brown, M., Mackridge, A., McCoy, E., 
Sumnall, H., Bellis, M., McVeigh, J., & (2008). A summary of the health harms of drugs. 
London: The Department of Health. 
 
42) McVeigh, J., & Evans-Brown, M. J. (2009). Anabolic steroids. Network, 25. 
 
Evans-Brown, M. J., & McVeigh, J. (2008). An Introduction to anabolic steroids. Sportex 
Medicine, (38), 20-26 
 
43) McVeigh, J., Hughes, K. E., Hounsome, J., & Bellis, M. (2003). Over a Decade of Drug Use 
Epidemiology. Centre for Public Health - Liverpool John Moores University 
 
44) Lenehan, P., & McVeigh, J. (1998). Anabolic Steroids: a guide for professionals. 
Liverpool: University of Liverpool. 
 
45) McVeigh, J. (1996). Survey of gym owners’ opinions on the use of performance 
enhancing drugs. Journal of Performance Enhancing Drugs, (1), 21-24. 
 
46) Korkia, P., Lenehan, P., & McVeigh, J. (1996). Non-medical use of androgens among 
women. Journal of Performance Enhancing Drugs, (2), 71-76. 
 
 
Appendix II.4 Recent examples of plenary and keynote conference presentations (Last 
2017/18) 
 
47) McVeigh, J (2018) Anabolic androgenic steroids & HIV: prevalence, risks & implications. 
Fourth Joint Conference of BHIVA with BASHH. Edinburgh: 17th - 20th April 2018 
 
48) McVeigh, J (2018) The public health implications of anabolic steroid use in the United 
Kingdom. A shot in the Dark: Steroids, IPEDs - the Hidden Harm Conference. Colchester. 
26th April 2018 
 
 
 49) McVeigh, J (2017) The range of IPEDs, user populations and motivations for use. Scottish 
Drugs Forum – Image and Performance Enhancing Drugs Conference  
Glasgow: 21st – 22nd March 2017 
 
50) McVeigh, J (2017) Image and performance enhancing drug use in the United Kingdom: 
challenges and implications. Doping in Sport, Doping in Society – Lessons, Themes and 
Connections Conference. Aarhus: 23rd – 25th August 2017 
 
51) McVeigh, J (2017) Changes in IPED use and concerns over last 20 years. Institute for 
Health Research Image and Performance Enhancing Drug Use Conference.  Liverpool: 3rd 
October 2017 
 
52) McVeigh, J (2017) Anabolic steroids: a global public health perspective. . Lisbon 
Addictions 2nd European conference on addictive behaviour and dependencies. Lisbon. 
23rd – 25th October: 2017 
 
